HHematologyThe study encyclopedia
⌘ K

Hematology

Term test edition
ArticleQuick referenceSources & coverage

From the Hematology study encyclopedia

Hematology is the study of blood, blood-forming tissues, and disorders of red cells, white cells, platelets, and coagulation. This article covers the hematology material in Weeks 9–12 of Foundations of Medicine.

The material is organized around normal blood-cell development, the anemias, bleeding and thrombosis, leukemias and marrow disorders, lymphoma, and myeloma. Related sections cover transfusion, pharmacology, radiation oncology, quality improvement, and critical appraisal.

The guide combines the 228-page Schulich review deck with the MedFriend Week 9–12 notes. Each topic includes source references and short review questions.

For the source list, lecture coverage, and the missing Week 11 note, see Sources & coverage. Conflicting or outdated source statements are identified in the relevant sections.
Navigation: use the contents or press / to search this article.Save an offline copy ↓

Week 9

Red cells & the anemias

Start with the blood count. Use cell size and the marrow response to organize the differential.

01

Blood cells, marrow and hemoglobin

Start with normal blood: which cells are present, where they are made, and what lets an erythrocyte carry oxygen.

What is in a tube of blood?

Blood contains plasma and formed elements. After centrifugation, a typical sample is approximately 55% plasma, 44% red cells and 1% buffy coat (white cells and platelets); these proportions vary with hematocrit.

  • Plasma is water plus dissolved proteins, electrolytes and other solutes. Albumin, immunoglobulins and coagulation proteins are important examples.
  • Serum is the liquid remaining after clotting. Fibrinogen and factors consumed during clotting are depleted; it is inaccurate to say that every coagulation protein disappears.
  • Erythrocytes carry oxygen; leukocytes provide immune defense; platelets help stop bleeding.

Meet the normal cells

CellStructure and lifespanUseful consequence
Red cellBiconcave disc, about 7–9 μm across; central pallor occupies roughly one third of its diameter. No nucleus or mitochondria. Lifespan about 120 days (roughly four months).The flexible membrane and cytoskeleton permit passage through small vessels. Glycolysis supplies energy without consuming transported oxygen.
PlateletAnucleate megakaryocyte fragment, about 1–3 μm; lifespan 7–10 days. Contains alpha granules, dense granules and lysosomes.Normally inactive, then activated at an injured vessel. Approximately two thirds circulate and one third are pooled in the spleen.
White cellNucleated; size and lifespan vary. Neutrophils, eosinophils and basophils are granulocytes; monocytes and lymphocytes are agranulocytes.Read the absolute differential, not just the total white count.

A red cell contains hemoglobin, water, ions and enzymes. Its membrane displays blood-group antigens. Aging or damaged red cells are removed mainly by splenic and hepatic macrophages.

White-cell roles at a glance

CellApproximate adult proportionMain role
Neutrophil50–70%Rapid defense against bacteria and fungi.
Lymphocyte25–35%B cells make antibodies; T cells coordinate or kill; natural killer cells provide innate cytotoxicity. Viral responses commonly cause lymphocytosis.
Monocyte4–6%Phagocytosis and antigen presentation; can become tissue macrophages or dendritic cells.
Eosinophil1–3%Parasites and allergic inflammation.
BasophilUsually <1%Histamine release and allergic responses.

These are teaching ranges; age and laboratory ranges matter, especially in children.

Hematopoiesis: one stem cell, many lineages

Hematopoiesis means production of all blood cells. A self-renewing hematopoietic stem cell gives rise to progressively committed progenitors, including colony-forming units (CFUs).

Myeloid branch: red cells, megakaryocytes/platelets, granulocytes and monocytes.
Lymphoid branch: B lymphocytes, T lymphocytes and natural killer cells.

Developmental sites shift from yolk sac (about weeks 2–3), through the aorta–gonad–mesonephros region and fetal liver (about weeks 5–6), with lymphoid tissues/thymus contributing around week 9 and spleen around week 16, to marrow becoming prominent after approximately six months of gestation. Children have active marrow in many bones; adult hematopoiesis is concentrated in the axial skeleton and proximal long bones.

The marrow niche includes vascular channels, stromal/reticular cells, fat, bone cells and extracellular matrix. Signals include stem cell factor, GM-CSF, G-CSF, M-CSF and interleukins. Erythropoietin (EPO) comes mainly from the kidney; thrombopoietin (TPO) mainly from the liver. G-CSF (filgrastim/Neupogen) stimulates neutrophil production. Hypoxia, blood loss and hemolysis increase the EPO drive to erythropoiesis.

Maturation and marrow sampling

  • Granulocytes: myeloblast → promyelocyte → myelocyte → metamyelocyte → band → segmented granulocyte. Normally, bands and mature segmented granulocytes circulate; earlier precursors stay in marrow.
  • Red cells: proerythroblast → basophilic → polychromatic → orthochromatic erythroblast → nucleus extruded → reticulocyte → mature erythrocyte. A reticulocyte still contains residual RNA.
  • Monocytes: monoblast → promonocyte → monocyte.
  • Platelets: megakaryoblast → maturing megakaryocyte → released platelet fragments.
  • Lymphocytes: pro-B → pre-B → mature B cell; analogous pro/pre stages precede mature T and NK cells, with distinct developmental signals and sites.

Megakaryocytes, blasts and nucleated red-cell precursors are expected in marrow, not normal adult peripheral blood. The teaching association is myeloblast predominance in AML, promyelocyte arrest in APL and preserved maturation in chronic-phase CML; actual leukemia classification also needs immunophenotyping and genetics.

An aspirate provides dispersed cells for morphology and ancillary tests. A trephine/core biopsy preserves architecture, cellularity and fibrosis. The posterior iliac crest is the usual site; the course mentions anterior tibial aspiration in selected infants. A Jamshidi core is commonly about 1–2 cm; touch imprints can be made before fixation. The teaching aspirate sample is about 1 mL, collected through a separate puncture that can use the same skin incision.

Hemoglobin: chains, genes and switching

Each hemoglobin molecule has four globin chains and four heme groups. Each heme contains ferrous iron (Fe²⁺) in a porphyrin ring and can bind one oxygen molecule: one hemoglobin can carry four O₂ molecules.

HemoglobinChainsTypical context
HbAα₂β₂Main adult hemoglobin, roughly 95–98%.
HbA₂α₂δ₂Small adult fraction, roughly 2–3.5%.
HbFα₂γ₂Dominant fetal form; usually <1–2% in adults. Higher oxygen affinity helps fetal oxygen uptake.

There are two alpha-globin genes on each chromosome 16: four alpha-gene copies in total. There is one beta-globin gene on each chromosome 11: two beta-gene copies. The fetal-to-adult switch accelerates after birth; falling HbF explains why severe beta-chain disorders become evident during infancy. Alpha-chain deficiency can affect fetal as well as adult hemoglobin.

Review questions
Which organs mainly produce EPO and TPO?

The kidney makes most erythropoietin; the liver makes most thrombopoietin.

Why can an alpha-globin defect cause disease before birth?

Alpha chains are required for fetal HbF as well as adult HbA; fetal gamma chains do not compensate for missing alpha chains.

What does a marrow core add to an aspirate?

It shows tissue architecture, cellularity, fibrosis and infiltration rather than only individual cells.

02

Read the CBC and blood film

Use hemoglobin to establish anemia, MCV to organize the differential, and reticulocytes to decide whether the marrow is responding.

Anemia is a finding, not a diagnosis

Anemia means hemoglobin below the appropriate reference interval. The review uses men <135 g/L and women <115 g/L; these are course reference values, not universal cutoffs. Age, pregnancy, laboratory method and clinical context alter interpretation.

General manifestations include fatigue, reduced exercise tolerance, dyspnea, pallor, tachycardia and sometimes chest discomfort or heart-failure symptoms. Jaundice points toward increased heme breakdown; pica, brittle/spoon nails, hair changes and restless legs suggest iron deficiency; neuropathy raises concern for B12 deficiency. Ask about bleeding, nutrition, medications, toxins, family history and the tempo of symptoms.

What the numbers mean

MeasurementMeaningInterpretation
HbHemoglobin concentrationDefines anemia; it is not the same as RBC count.
Hematocrit (Hct)Fraction of blood volume occupied by red cellsFalls with anemia; dehydration can increase it by concentrating blood.
MCVMean red-cell volume, in femtolitres<80 microcytic; 80–100 normocytic; >100 macrocytic in this course.
MCH / MCHCHb mass per cell / Hb concentration within red cellsMCHC is a concentration, not simply the amount of Hb in a cell.
RDWVariation in red-cell sizeRaised in anisocytosis; often high in iron/B12/folate deficiency and mixed populations.
ReticulocytesYoung red cells recently released by marrowHigh: response to loss/destruction or treatment. Low or inappropriately normal: insufficient production.
WBC + differentialTotal white cells and their five principal typesLook for associated cytopenias, reactive changes or abnormal cells.
Platelets / MPVNumber / mean platelet volumeAssess bleeding risk, marrow patterns and reactive thrombocytosis.

The Coulter principle counts electrical pulses as cells cross an aperture in conductive liquid. Pulse size reflects cell volume; cell clumps can therefore distort counts and MCV.

The first decision tree

Low Hb → read MCV and examine the smear → check the reticulocyte response.
Small cells: investigate iron and globin production.
Normal-sized cells: distinguish underproduction from bleeding/hemolysis.
Large cells: distinguish impaired DNA synthesis from other causes.
Any MCV + suspected hemolysis: check hemolysis markers and DAT.

A normal MCV is an average: simultaneous microcytic and macrocytic disorders can cancel each other. A “normal” reticulocyte percentage may be inadequate in an anemic patient; use the absolute count and, when appropriate, a corrected count or production index. After acute bleeding, the reticulocyte rise takes time.

Describe cells before naming a disease

Anisocytosis means variable size; poikilocytosis means variable shape. Hypochromia means increased central pallor from reduced hemoglobinization. Polychromasia is a blue-grey tint from young RNA-containing red cells.

Film findingMechanism / association
ElliptocytesElongated cells: hereditary elliptocytosis or severe iron deficiency.
Target cellsExcess membrane relative to cell contents: thalassemia, liver disease, hyposplenism; sometimes severe iron deficiency.
AcanthocytesIrregular membrane projections: altered membrane lipids, especially liver disease; can occur with hyposplenism.
SpherocytesSmall dense cells lacking central pallor: hereditary spherocytosis or immune hemolysis.
Bite / blister cellsOxidative damage, especially G6PD deficiency; splenic removal of denatured Hb leaves a bite.
SchistocytesFragments from mechanical shearing: valves, DIC, TTP, HUS and other microangiopathies.
Sickle cellsDeoxygenated HbS polymerization distorts the cell.
TeardropsMarrow fibrosis or infiltration; interpret with the rest of the film.
RouleauxStacks of coins due to increased plasma proteins, especially paraproteins or inflammation.
AgglutinationIrregular clusters, often from cold-reacting IgM antibodies.

Inclusions and white-cell clues

  • Howell–Jolly bodies: residual nuclear DNA; suggest impaired splenic clearance or absent spleen.
  • Heinz bodies: precipitated, denatured hemoglobin; a special supravital stain may be needed.
  • Pappenheimer bodies: iron-containing granules.
  • Basophilic stippling: aggregated ribosomal material; consider lead exposure or thalassemia.
  • Hypersegmented neutrophils + oval macrocytes: megaloblastic process.
  • Hypogranular, hyposegmented neutrophils: dysplasia, including pseudo-Pelger–Huët changes in MDS.
  • Nucleated RBCs + immature myeloid cells: a leukoerythroblastic picture, suggesting marrow stress or infiltration.

The illustrated morphology atlas also labels stomatocytes (slit or mouth-shaped central pallor), echinocytes/burr cells (regular short projections), helmet cells (a fragmented-cell form), Cabot rings (thin ring/loop inclusions) and HbC/HbSC crystals. These are additional descriptive clues, not diagnoses by themselves. Hypochromia is sometimes graded 1+ to 4+ as central pallor increases.

The illustrated CBC: read all three lines

The source example has Hb 83 g/L, MCV 86.2 fL, WBC 0.9 × 10⁹/L, neutrophils 0.3 × 10⁹/L and platelets <10 × 10⁹/L. This is normocytic anemia within pancytopenia, with severe neutropenia and thrombocytopenia. A normal-sized red cell does not make this a reassuring CBC. Evaluate marrow production and dangerous complications rather than stopping at the anemia label.

Review questions
Can a patient with normal MCV have both iron and B12 deficiency?

Yes. Small and large cell populations can average to a normal MCV; RDW and the smear help expose the mixture.

A patient has spherocytes. Which test helps distinguish immune hemolysis from hereditary spherocytosis?

The direct antiglobulin test (DAT). Positive IgG/complement supports immune coating, while hereditary spherocytosis is usually DAT-negative.

Which neutrophil finding separates classic megaloblastosis from typical MDS?

Hypersegmentation supports megaloblastosis; hyposegmentation with hypogranularity supports dysplasia.

03

Iron biology and microcytic anemia

Microcytosis usually reflects too little hemoglobin synthesis: not enough usable iron, a heme-synthesis problem, or too little globin.

TAILS is a mechanism checklist

Thalassemia, Anemia of chronic inflammation, Iron deficiency, Lead poisoning, Sideroblastic anemia. Thalassemia reduces globin production; the others impair iron availability or heme synthesis. Precursors continue dividing while hemoglobin accumulation lags, producing small, pale cells.

How iron reaches hemoglobin

About 20 mg of iron is recycled daily from old red cells, whereas only about 1–2 mg is normally absorbed and lost each day. Most body iron is in hemoglobin; the rest is stored or incorporated into other proteins. Plasma transferrin carries a small, rapidly exchanged pool.

  1. Dietary heme iron is readily absorbed. Non-heme ferric iron (Fe³⁺) is reduced to ferrous iron (Fe²⁺), aided by duodenal cytochrome B and an acidic environment.
  2. Divalent metal transporter 1 (DMT1) takes Fe²⁺ into the enterocyte, mainly in the proximal small intestine.
  3. Ferroportin exports iron. Hephaestin helps oxidize it so transferrin can carry it through plasma.
  4. Ferritin stores iron safely inside cells; its 24-subunit protein shell can hold approximately 4500 iron atoms. Hemosiderin is another storage form.
  5. Hepcidin, made by the liver, reduces ferroportin activity. High iron and inflammation increase hepcidin, restricting gut absorption and macrophage iron release.

Free iron can promote oxidative injury, which is why transport and storage proteins matter. Heme-synthesis enzyme defects can also produce porphyrias, distinct from simple dietary iron deficiency.

The lecture schematic uses approximately 2500 mg in circulating RBCs, 1500 mg in storage and 4 mg in plasma to illustrate the different pool sizes. Actual totals vary substantially with body size, sex and iron status; the important relationship is a large RBC/storage pool and a small transport pool.

Read iron studies as a pattern

PatternFerritinSerum iron / saturationTransferrin or TIBCOther clues
Iron deficiencyLowLowHighRDW often high; platelets may rise.
InflammationNormal or highLowLow or normalRaised inflammatory markers; iron trapped in stores.
Thalassemia traitUsually normalUsually preservedUsually normalRBC count relatively high for the Hb/MCV; RDW often normal.
Sideroblastic processOften highOften highVariableRing sideroblasts in marrow; RDW may rise; possible iron overload.

Ferritin is an acute-phase reactant: a low value strongly supports iron depletion, but a normal/high value during inflammation does not reliably exclude coexisting deficiency. Soluble transferrin receptor often rises in iron deficiency; red-cell zinc protoporphyrin can also increase when iron cannot be incorporated into heme. These and other tests can help in selected cases. Thalassemia is typically hypochromic; an elevated MCHC is not its defining laboratory feature.

Iron deficiency: identify the missing iron

  • Loss: menstrual bleeding or fibroids, gastrointestinal bleeding (ulcer, malignancy, other lesions), blood donation, urinary loss, bleeding disorders and less common chronic losses. Melena suggests upper gastrointestinal bleeding.
  • Poor absorption: celiac disease, gastric bypass/gastrectomy, atrophic gastritis, H. pylori-associated disease and relevant medications.
  • Increased need: growth, pregnancy or brisk erythropoiesis.
  • Low intake: an inadequate diet; assess actual iron intake rather than assuming every vegetarian diet is deficient.

Less common associations in the notes include chronic intravascular hemolysis with hemoglobinuria, pulmonary hemosiderosis and repetitive endurance-related losses. Iron stores can be depleted before Hb falls: iron deficiency and iron-deficiency anemia are not synonymous.

Pica, koilonychia (spoon-shaped nails), glossitis, restless legs, hair/nail changes and dysphagia from esophageal webs support the diagnosis. The film often shows hypochromia, anisopoikilocytosis and elliptocytes. Start with CBC, ferritin and film; marrow iron assessment is rarely needed in a straightforward case. Replacing iron must be paired with finding the cause.

Inflammation: iron present, iron unavailable

Inflammatory signals, especially IL-6, increase hepcidin. Iron becomes sequestered in macrophages; erythropoietin responsiveness falls and red-cell survival may shorten. The anemia is commonly normocytic at first, sometimes mildly microcytic; marked microcytosis should prompt a search for another or additional cause.

Examples include chronic infection (tuberculosis, osteomyelitis, endocarditis, abscesses, HIV), rheumatoid arthritis, lupus, inflammatory bowel disease and malignancy. The notes also list chronic heart/liver disease and unexplained cases; mixed mechanisms are common in these settings. The slide’s “IBS” example should be read as IBD: irritable bowel syndrome is not the classic inflammatory cause. Treat the underlying disease; transfusion and erythropoiesis-stimulating therapy are selected, context-dependent measures.

Lead and sideroblastic anemia

Sideroblastic anemia means impaired incorporation of iron into heme. Iron accumulates in mitochondria around erythroblast nuclei, producing ring sideroblasts in marrow, not simply rings on a routine peripheral smear.

Causes include inherited defects, myelodysplasia, alcohol, medications/toxins and vitamin B6 deficiency or antagonism (for example, isoniazid). Ask about industrial exposure and old paint when lead is plausible. Peripheral findings can include basophilic stippling and Pappenheimer bodies; confirm suspected lead toxicity with a blood lead measurement.

Remove the exposure and treat the cause. Pyridoxine helps selected B6-responsive cases; lead chelation depends on toxicity severity. Severe chronic cases may need transfusion support and specialist management. Sideroblastic disorders, especially MDS-associated forms, are not invariably microcytic.

Review questions
Why can ferritin be high while serum iron is low?

Inflammation increases hepcidin and traps iron in storage cells; ferritin also rises as an acute-phase protein.

A very low MCV accompanies a relatively high RBC count and normal ferritin. What rises on the differential?

Thalassemia trait, particularly when the smear shows target cells and RDW is relatively normal.

Where are ring sideroblasts identified?

In bone-marrow erythroid precursors stained for iron; they are not the same as peripheral blood target cells.

04

Thalassemia and hemoglobin analysis

Thalassemia is a quantitative globin-production problem. The imbalance damages erythroid precursors and circulating red cells.

Why globin imbalance causes anemia

Reduced synthesis of one chain leaves an excess of its partner. Unpaired chains damage developing cells, causing ineffective erythropoiesis, and shorten the survival of circulating red cells. The result combines underproduction and hemolysis.

Clues include lifelong microcytosis, family history, target cells, basophilic stippling, jaundice and splenomegaly. More severe disease can cause growth impairment, marrow expansion with skeletal changes and iron overload. Geographic ancestry informs probability—alpha variants are common in parts of Africa and Asia, beta variants in Mediterranean and many other populations—but does not establish or exclude the diagnosis.

Alpha thalassemia: count four gene copies

Functional copies lostUsual phenotypeKey point
1 of 4Silent carrierUsually minimal hematologic change.
2 of 4Alpha-thalassemia traitMicrocytosis with mild or absent anemia. Cis versus trans arrangement matters for reproductive risk.
3 of 4HbH diseaseHemolytic anemia, often splenomegaly; severity varies.
4 of 4Hb Bart hydrops fetalis syndromeProfound fetal anemia; historically often fatal without specialized fetal/neonatal treatment.
Correction to the review diagram: HbH is β₄; Hb Bart is γ₄. Both arise from deficient alpha-chain production. Hb Bart is not an alpha tetramer or a beta-thalassemia marker. GeneReviews: alpha-thalassemia.

Beta thalassemia: quantity matters as well as copy count

There are two beta-globin gene copies. β⁰ alleles make no beta chain; β⁺ alleles make less. One affected copy commonly causes minor/trait. Two clinically important variants may cause intermedia or major; genotype and modifying factors determine severity, so “intermedia = one abnormal copy” is an oversimplification.

Severe beta-thalassemia emerges as HbF declines during infancy. Trait often has increased HbA₂; severe disease often has increased HbF, with very little or no HbA in β⁰/β⁰ disease. Transfusion history can alter measured proportions.

Tests and treatment principles

Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) separates and quantifies hemoglobin types. Alpha trait may have normal adult hemoglobin fractions, so a normal electrophoresis does not exclude it; molecular testing and selected HbH inclusion studies can help.

Trait generally needs explanation and reproductive counseling, not automatic iron. Give iron only for demonstrated coexisting deficiency. More severe disease may need regular or intermittent transfusions, iron-overload monitoring and chelation (the course example is deferoxamine). Selected patients may be eligible for definitive stem-cell-based treatment. Family testing and genetic counseling clarify the risk to future children.

Review questions
Why can electrophoresis be normal in alpha-thalassemia trait?

All major adult hemoglobins need alpha chains, so their relative proportions may remain normal despite reduced overall alpha production.

Which tetramers are HbH and Hb Bart?

HbH is beta4; Hb Bart is gamma4.

Why can repeated transfusion create another disease problem?

Transfused iron accumulates because the body has no effective regulated pathway for excreting excess iron, risking organ injury.

05

Normocytic anemia, marrow failure and MDS

A normal-sized red cell does not tell you whether production is adequate. The reticulocyte response is the key first fork.

ABCD and the reticulocyte fork

Acute blood loss, Bone marrow failure, Chronic disease and Destruction organize normocytic anemia.

Reticulocytes appropriately increased: look for bleeding, hemolysis or recovery after treatment.
Reticulocytes low or inappropriately normal: evaluate kidney function, inflammation, nutrition, medications and marrow disease.

Chronic kidney disease reduces EPO production. Hypothyroidism can cause normocytic as well as macrocytic anemia. The final review map also lists severe vitamin C deficiency: poor iron absorption and bleeding can both contribute. Anemia of inflammation restricts iron and marrow responsiveness. The slide’s direct arrow from low reticulocytes to marrow biopsy is a simplification: investigate common reversible causes first; unexplained cytopenias, abnormal morphology or suspected marrow disease justify aspirate/core assessment.

Acute hemorrhage may be gastrointestinal, menstrual/uterine, urinary or internal. The initial Hb can underestimate the severity of very recent blood loss before fluid equilibration. Control bleeding and assess hemodynamics; transfusion depends on the clinical situation.

Pure red cell aplasia: one lineage fails

Pure red cell aplasia (PRCA) causes anemia with profound reticulocytopenia and absent or greatly reduced erythroid precursors. White cells and platelets are relatively preserved. It is not defined by increased erythroblasts or polychromasia on the film.

Causes include congenital Diamond–Blackfan anemia, acquired immune disease, drugs/toxins, infections, tumors and other marrow disorders. The course also lists pregnancy and transient erythroblastopenia of childhood. Investigation is guided by the setting; treatment targets the cause, with transfusion or immunosuppression when appropriate. Splenomegaly is not an expected defining feature of isolated PRCA.

Two particularly useful acquired associations are parvovirus B19, which suppresses erythroid precursors, and thymoma. In someone with baseline chronic hemolysis, parvovirus-related arrest can cause a profound transient aplastic crisis. NHS PRCA guidance.

Aplastic anemia: all three lines fail

Stem-cell failure produces pancytopenia with hypocellular, fatty marrow. Anemia causes fatigue/pallor, thrombocytopenia causes bruising/bleeding, and neutropenia increases infection risk. Many cases are acquired and immune-mediated; medications, chemicals, radiation and inherited disorders also matter.

Inherited clueFeatures emphasized in the notes
Fanconi anemiaShort stature, abnormal thumbs/radii, pigmentation, renal and cardiac anomalies.
Dyskeratosis congenita / telomere disorderNail dystrophy, oral leukoplakia and reticular pigmentation, particularly neck/upper trunk.

Support includes appropriate blood components and prompt treatment of infection. Febrile neutropenia is an emergency requiring urgent empiric antibiotics; transfusion is provided only for its own indication. Definitive options include stem-cell transplantation or specialist immunosuppressive regimens, commonly antithymocyte globulin with cyclosporine. Corticosteroids alone are not a general definitive treatment for aplastic anemia.

Myelophthisis: marrow is displaced

Myelophthisic anemia results when normal marrow is crowded out by fibrosis, leukemia/lymphoma, metastatic solid cancer or other infiltrative disease, including rare granulomatous infiltration such as tuberculosis. The film may be leukoerythroblastic: nucleated red cells and immature granulocytes appear together, often with teardrop cells.

Splenomegaly can accompany myelofibrosis because blood production shifts outside marrow. Aspirate can be difficult in fibrotic marrow; the core is especially helpful. Treatment addresses the infiltrative disease while supporting blood counts.

MDS: cells are produced badly

Myelodysplastic syndromes/neoplasms (MDS) are clonal stem-cell disorders with ineffective hematopoiesis, dysplasia, peripheral cytopenias and a risk of progression to acute myeloid leukemia (AML). Unlike aplasia, the marrow is often cellular despite low circulating counts.

MDS predominates in older adults. The source quotes an incidence of roughly 3–4 per 100,000 and a median age of 65–70; exact estimates vary by population. About 80% present with anemia, 40% with neutropenia and 30% with thrombocytopenia in the teaching notes. Anemia is often macrocytic, sometimes normocytic. Prior chemotherapy, radiation or toxin exposure raises suspicion.

Clues include unexplained persistent cytopenias, hypogranular neutrophils and pseudo-Pelger–Huët hyposegmentation. Check CBC/film, relevant reversible causes, ferritin in transfused patients, and marrow morphology, flow cytometry, cytogenetics and molecular findings. Dysplasia alone is not enough if nutritional or other mimics have not been considered.

MDS risk and treatment

The original International Prognostic Scoring System (IPSS) considers marrow blast percentage, cytogenetic abnormalities and the number of cytopenic lineages. Contemporary models refine risk using additional variables. The exam principle is that risk determines whether the main goal is improving counts/quality of life or altering progression.

  • Lower risk: individualized transfusion support and selected erythropoiesis-stimulating treatment; G-CSF may be added selectively.
  • Higher risk: hypomethylating drugs such as azacitidine or decitabine, and consideration of transplant or other disease-directed treatment.
  • del(5q): an uncommon subgroup (the source estimates <10% of MDS) may have macrocytic anemia with normal/high platelets and can respond to lenalidomide.
  • Stem-cell transplant: potentially curative for suitable patients, balanced against its risks.
Do not turn a review threshold into an automatic order. Hb 70 g/L is a common restrictive transfusion reference, but symptoms and context matter. Ferritin >1000 μg/L can prompt assessment of transfusional iron overload; chelation also depends on transfusion burden, ongoing needs and expected benefit. BSH MDS guidance.
Review questions
What separates PRCA from aplastic anemia?

PRCA primarily removes the erythroid lineage; aplastic anemia causes pancytopenia with hypocellular fatty marrow.

What does a leukoerythroblastic smear suggest?

Marrow stress or displacement, especially infiltration/fibrosis when accompanied by teardrops.

Why can MDS produce low blood counts despite a cellular marrow?

Hematopoiesis is ineffective: abnormal precursors fail to mature and survive normally.

06

Hemolysis and the direct antiglobulin test

First establish accelerated red-cell destruction. Then use the smear and DAT to identify its mechanism.

The shared biochemical signature

Hemolysis releases hemoglobin and shortens red-cell survival. Heme becomes bilirubin, globin is broken into amino acids, and iron is recycled by macrophages.

FindingWhy it changes
Indirect bilirubin ↑More heme is processed into unconjugated bilirubin.
LDH ↑Cell injury releases lactate dehydrogenase.
Haptoglobin ↓It binds free plasma hemoglobin and is consumed/cleared.
Reticulocytes ↑Marrow compensates if it has adequate nutrients and function.

These findings are supportive, not individually specific. Reticulocytes may fail to rise with concomitant marrow suppression, deficiency or very early disease. Hemolysis can have a microcytic, normal or macrocytic MCV, depending on its cause and the reticulocyte contribution.

Intravascular versus extravascular

Intravascular hemolysis occurs within vessels and can produce plasma free hemoglobin, hemoglobinuria and hemosiderinuria. Mechanical shearing, complement-mediated destruction and PNH are examples.

Extravascular hemolysis occurs when splenic/hepatic macrophages remove abnormal or coated cells. Jaundice, splenomegaly and pigment gallstones may develop. Hereditary spherocytosis and much immune hemolysis follow this pattern. Some disorders cause both.

DAT: are antibodies or complement on the RBC?

The direct antiglobulin test (direct Coombs test) detects immunoglobulin and/or complement already attached to the patient’s red cells. A positive test plus evidence of hemolysis supports an immune process. A positive DAT alone does not prove clinically significant hemolysis, and a minority of immune cases can be DAT-negative.

Autoimmune antibodies target one’s own red cells. Alloimmune antibodies target foreign RBC antigens after exposure through transfusion or pregnancy; they explain important transfusion reactions and hemolytic disease of the fetus/newborn.

Warm autoimmune hemolytic anemia

Warm AIHA usually involves IgG reacting near 37°C. Splenic macrophages remove antibody-coated membrane; the reduced surface-area-to-volume ratio creates spherocytes. Hemolysis is predominantly extravascular, with jaundice, reticulocytosis and sometimes splenomegaly.

DAT is usually positive for IgG, sometimes with C3; warm antibodies are not universally incapable of activating complement. Causes include primary/idiopathic disease, lupus, CLL or other lymphoid malignancy and drugs. The review lists methyldopa, penicillin and quinine as medication associations.

Glucocorticoids are a usual initial treatment; address the cause, support hematopoiesis and transfuse when clinically necessary. The older slide sequence places splenectomy second. Rituximab is now commonly preferred for relapsed/refractory disease; splenectomy remains an option in selected patients. ASH review of AIHA management.

Cold agglutinin disease and syndrome

Cold-reacting IgM binds RBCs in cooler peripheral blood and activates complement. On warming, IgM may detach while complement remains, so the DAT is characteristically C3-positive. Clumping on the film and spuriously abnormal automated indices can be clues; cold-related acral symptoms can occur.

Associations include Mycoplasma infection, infectious mononucleosis and B-cell lymphoproliferative disorders. Cold agglutinin disease is commonly a chronic clonal process; cold agglutinin syndrome can be secondary to another illness.

Keep warm and treat associated disease. Steroids and splenectomy are generally less useful than in warm AIHA. The statement that all immunosuppressive treatment is ineffective is too broad: rituximab-based therapy is effective in selected patients, and complement inhibition with sutimlimab treats hemolysis. International AIHA consensus; sutimlimab trial.

Review questions
Why does the DAT often detect C3 rather than IgM in cold agglutinin disease?

IgM can detach as blood warms while complement fragments remain bound to the red cell.

Why do both warm AIHA and hereditary spherocytosis make spherocytes?

Both reduce membrane surface area relative to cell volume, although one is immune-mediated and the other arises from inherited membrane defects.

Does a high LDH prove hemolysis?

No. LDH is nonspecific; interpret it with bilirubin, haptoglobin, reticulocytes, smear and clinical context.

07

Membrane, enzyme and acquired nonimmune hemolysis

A negative DAT directs attention toward intrinsic red-cell defects and nonimmune destruction, while the film often narrows the next test.

Hereditary spherocytosis

Defects in spectrin, ankyrin, band 3 or protein 4.2 weaken the membrane skeleton. Membrane is lost, cells become spherical and poorly deformable, and the spleen removes them. Inheritance is often autosomal dominant.

Typical findings are DAT-negative hemolysis, spherocytes, jaundice, splenomegaly and pigment gallstones. Confirmation commonly uses eosin-5-maleimide (EMA) binding by flow cytometry, which reflects membrane-protein abnormalities, with other specialized tests where needed.

Folate supports increased erythropoiesis. Splenectomy can reduce severe hemolysis but does not correct the membrane defect; infection risks require vaccination, education and age/context-specific antimicrobial prophylaxis. Hereditary elliptocytosis is another membrane disorder and produces elongated rather than spherical cells.

G6PD deficiency: an antioxidant failure

Glucose-6-phosphate dehydrogenase supplies NADPH, which keeps glutathione reduced. Without adequate reduced glutathione, oxidants damage hemoglobin and the cell membrane. Inheritance is X-linked; prevalence is higher in many African, Mediterranean and Asian populations.

Episodes may follow infection, fava beans or oxidant drugs. The course mentions antimalarials, sulfonamides and aspirin; actual medication risk is drug- and dose-specific, so this list is not a blanket rule for every member of a class. Hemolysis can be intravascular and extravascular.

Denatured Hb forms Heinz bodies. Splenic removal produces bite cells; blister cells also occur. Measure G6PD enzyme activity, but a normal value during or soon after an attack can be misleading because the most deficient older cells have been destroyed and reticulocytes have greater activity. Repeat testing after recovery when suspicion persists. BSH laboratory guideline.

Avoid established triggers, treat infection, and provide supportive treatment/transfusion when needed. Folate may be useful with sustained increased turnover. The slide’s “splenectomy if severe” is not routine management of the common episodic form; rare chronic hemolytic variants need specialist assessment.

The practical priorities are trigger avoidance and supportive care; the WHO educational modules emphasize removing offending agents and transfusing for symptomatic anemia when needed.

Schistocytes: think shear stress

Microangiopathic hemolytic anemia (MAHA) means RBC fragmentation in abnormal small vessels. Major examples are TTP, HUS and DIC. Other causes include severe hypertension, pre-eclampsia/HELLP, malignancy, vascular inflammation and other endothelial injury.

Mechanical valves or paravalvular leaks can also shear cells. Repetitive physical trauma, such as prolonged running or hand percussion, is another mechanism. Check platelet count, creatinine, coagulation tests and fibrinogen alongside the clinical picture. MAHA with thrombocytopenia can signal a time-critical thrombotic microangiopathy; it is not an indication to wait for every confirmatory result.

Infection, burns and PNH

  • Malaria: parasites infect RBCs; rupture and splenic clearance cause anemia. Fever, chills, travel/exposure history, splenomegaly and parasites on the film are clues.
  • Clostridial sepsis: toxin-mediated membrane injury can cause dramatic hemolysis with microspherocytes. This is an emergency.
  • Thermal injury: extensive burns directly damage red cells, producing fragments and microspherocytes.
  • Paroxysmal nocturnal hemoglobinuria (PNH): an acquired clonal PIGA-associated defect leads to loss of protective GPI-anchored proteins, making cells vulnerable to complement. It is classically intravascular and may accompany marrow failure and thrombosis. It is not antibody-mediated AIHA; flow cytometry establishes the characteristic deficient population.

Pyruvate kinase deficiency: another enzyme defect

The hemolysis summary diagram also names pyruvate kinase deficiency. This inherited glycolytic defect reduces ATP production and causes chronic nonspherocytic hemolysis. It should not be memorized as a specific cause of bite cells: morphology may be nonspecific, and echinocytes can occur. Enzyme activity and molecular testing establish the diagnosis. International diagnostic consensus.

Review questions
Why can G6PD testing be falsely normal during an attack?

The most enzyme-deficient older RBCs may already be destroyed; surviving young cells and reticulocytes can have higher measured enzyme activity.

Which film finding prompts evaluation for TTP, HUS or DIC?

Schistocytes, particularly when accompanied by thrombocytopenia and organ injury.

Is PNH an autoimmune hemolytic anemia?

No. It is an acquired clonal defect in complement protection rather than RBC-targeting autoantibodies.

08

Sickle cell disease and its emergencies

HbS causes both chronic hemolysis and episodic vaso-occlusion. The genotype, fetal hemoglobin level and clinical context shape severity.

One amino-acid change, two kinds of injury

HbS has valine instead of glutamate at position 6 of beta globin. Deoxygenated HbS polymerizes, making RBCs rigid and sickle-shaped. Repeated injury causes hemolysis; impaired flow and cellular adhesion cause ischemic vaso-occlusion. Hypoxia, dehydration, infection, acidosis and cold can precipitate episodes.

HbC is a different beta-chain variant, with lysine replacing glutamate. HbSC is clinically significant sickle cell disease because the second allele modifies the behavior of HbS; the presence of HbS alone does not determine the phenotype.

Read the two beta alleles

GenotypeMeaning
HbAAUsual adult beta-chain genotype.
HbASSickle cell trait: one HbS and one normal beta allele.
HbSSSickle cell anemia: two HbS alleles.
HbSCCompound heterozygous sickle cell disease.
HbS/β⁺-thalassemiaThe other allele makes reduced normal beta chains; some HbA can be present.
HbS/β⁰-thalassemiaThe other allele makes no beta chains; no HbA from that allele.

If both parents have HbAS, each pregnancy has a 25% chance of HbSS, 50% of HbAS and 25% of HbAA. These are independent probabilities for every pregnancy. Trait confers partial protection against severe falciparum malaria; it is not complete protection from infection.

People with trait are usually well but can have hematuria and complications under extreme exertion, hypoxia or dehydration. Renal medullary carcinoma is a rare association. Ocular injury with hyphema requires particular care because sickling can compromise outflow and raise pressure.

When disease becomes apparent

High fetal hemoglobin inhibits sickling early in life. As HbF falls, symptoms can begin around 5–6 months; waiting until age three would miss early disease. Newborn screening is therefore essential. CDC: sickle cell disease.

Confirm the hemoglobin pattern with electrophoresis/HPLC and appropriate specialist testing. A sickle-solubility test such as Sickledex detects HbS but cannot adequately characterize the genotype or replace newborn screening; high HbF can limit its usefulness in infants. The smear may show sickle cells, target cells and evidence of functional hyposplenism. HbF levels vary and are not always markedly elevated.

Complications to recognize immediately

  • Vaso-occlusive pain episode: ischemic pain; dactylitis is painful hand/foot swelling in young children.
  • Acute chest syndrome: a new pulmonary infiltrate with compatible respiratory symptoms and/or fever. It can deteriorate rapidly.
  • Stroke: acute neurologic change is an emergency.
  • Splenic complications: early splenic sequestration can cause abrupt anemia and shock; repeated infarction eventually causes functional asplenia/splenic atrophy.
  • Infection: impaired splenic function increases vulnerability, especially to encapsulated bacteria. Fever warrants urgent assessment.
  • Chronic injury: cumulative organ damage, including renal, pulmonary, bone and neurologic complications; chronic hemolysis also predisposes to pigment gallstones.

Care principles

Hydroxyurea increases HbF and reduces important sickling complications. Preventive care includes vaccination, penicillin prophylaxis in young children (classically through age five in relevant genotypes), follow-up and selected transfusion programs. Stem-cell transplantation can be curative for suitable patients.

During a pain episode, assess for infection and other emergencies, provide prompt individualized analgesia, correct dehydration and treat the trigger. Oxygen is given for hypoxemia, not automatically to every well-oxygenated patient; excessive IV fluids can worsen pulmonary complications. Cold packs should be avoided. Canadian Paediatric Society acute-care guidance.

Acute chest syndrome generally requires admission, respiratory support as needed, antibiotics and consideration of simple or exchange transfusion with hematology. Uncomplicated pain alone does not automatically require transfusion. Believe and assess the patient’s pain; use respectful person-first language.

Review questions
Why does sickle disease often become symptomatic several months after birth?

Protective fetal hemoglobin declines while adult beta-chain hemoglobin production rises.

What is the key difference between HbS/β⁺ and HbS/β⁰?

β⁺ permits some normal beta-chain production and HbA; β⁰ does not.

Should all painful sickle episodes receive oxygen and aggressive IV fluids?

No. Treat hypoxemia and dehydration when present; avoid routine oxygen in a well-oxygenated patient and avoid overhydration.

09

Macrocytosis, vitamin B12 and folate

Large red cells may reflect impaired DNA synthesis, altered membrane lipids, reticulocytosis, dysplasia or an automated-count artifact.

ABCDEF and the smear

Alcohol, B12 deficiency, Compensatory reticulocytosis, Drugs/dysplasia, Endocrine disease (hypothyroidism), Folate deficiency/fetus-related increased demand.

Begin with CBC, reticulocytes and smear, then assess B12/folate, medications, liver tests and thyroid function as indicated. Oval macrocytes and hypersegmented neutrophils support a megaloblastic process; large round cells with normal neutrophil segmentation favor a nonmegaloblastic mechanism.

Megaloblastosis: DNA lags behind cytoplasm

B12/folate deficiency or drugs that impair nucleotide synthesis delay nuclear maturation while cytoplasmic growth continues: nuclear–cytoplasmic asynchrony. Ineffective erythropoiesis can produce low reticulocytes despite a hypercellular marrow, high LDH/indirect bilirubin and, when severe, pancytopenia.

Drug examples include methotrexate, trimethoprim and other antimetabolite chemotherapy. MDS can also cause macrocytosis and megaloblastoid changes, but the full dysplastic picture and underlying clonal process matter.

B12 and folate: compare the pathways

FeatureB12Folate
StoresApproximately 3–5 years; total body stores are roughly 2–5 mg.A few months; deficiency can appear more quickly.
AbsorptionIntrinsic factor from gastric parietal cells binds B12 in the small bowel; uptake occurs in the terminal ileum.Predominantly proximal small intestine, especially jejunum.
Major dietary sourcesAnimal foods and fortified foods/supplements. Unfortified legumes are not a reliable source.Leafy vegetables, legumes and fortified grains; preparation and overall diet affect intake.
HomocysteineCan increase.Can increase.
Methylmalonic acid (MMA)Can increase.Usually not increased by isolated folate deficiency.
Characteristic neurologic diseasePeripheral neuropathy, impaired vibration/proprioception, gait or cognitive changes.Does not cause the characteristic B12 myeloneuropathy.

B12 is a cofactor for methionine synthase (homocysteine → methionine) and methylmalonyl-CoA mutase (methylmalonyl-CoA → succinyl-CoA). Folate supports one-carbon transfer, including thymidylate synthesis. MTHFR makes 5-methyl-THF; B12-dependent methionine synthase helps regenerate THF—the website’s reaction direction is reversed. NIH folate reference; NIH B12 reference.

Why each vitamin becomes deficient

  • B12 intake: prolonged inadequate intake, including an unsupplemented vegan diet or malnutrition.
  • B12 gastric causes: autoimmune gastritis/pernicious anemia, gastrectomy, mucosal atrophy or rare intrinsic-factor defects.
  • B12 intestinal causes: Crohn disease involving terminal ileum, ileal resection, selected infections/parasites or rare receptor defects.
  • Folate intake: inadequate diet, alcohol use, food insecurity and inappropriate infant feeding such as unfortified goat milk.
  • Folate absorption or drugs: extensive jejunal disease/resection; anticonvulsants, sulfasalazine and antifolate drugs; the source also lists oral contraceptives, although this is not a common explanation for major clinical deficiency.
  • Folate demand: pregnancy/lactation, prematurity, chronic hemolysis, dialysis losses and high cell turnover, including severe exfoliative skin disease.

B12 deficiency may also cause mood/cognitive symptoms, altered taste/smell or optic problems; affected infants may have feeding difficulty and developmental regression/delay. Glossitis, pallor, mild jaundice and gastrointestinal symptoms can occur with either deficiency.

Testing and the folate trap

Measure B12 and use MMA/homocysteine selectively when results or clinical suspicion need clarification; kidney dysfunction can elevate these metabolites. Investigate the cause, including intrinsic-factor antibodies when pernicious anemia is suspected. The Schilling test is historical and generally unavailable; colonoscopy is not a routine test for every macrocytosis case.

Do not give folate alone when B12 deficiency remains plausible. Folate may improve the blood count while B12-related neurologic injury continues. B12 neurologic disease can occur without obvious macrocytosis or anemia.

Nonmegaloblastic explanations

CauseHow it enlarges the measured cellsUseful clue
Liver disease / alcoholMembrane lipid changes; alcohol can also suppress marrow and coexist with folate deficiency.Round macrocytes, target cells; evaluate liver disease and nutrition.
ReticulocytosisReticulocytes are larger than mature RBCs.Polychromasia and a genuine increased young-cell population after bleeding/hemolysis.
Cold agglutinationClumps can be counted as large cells.Discordant automated indices; sample warming/reanalysis may clarify.
High plasma proteins / rouleauxAggregation can interfere with measurement.Consider myeloma or inflammation; distinguish stacked coins from immune clumps.
HypothyroidismReduced/altered erythropoiesis.Cold intolerance, weight gain, constipation, hair change, fatigue or bradycardia; check TSH.
MDSAbnormal clonal maturation.Other cytopenias and dysplastic neutrophils.

Reticulocytosis-related macrocytosis is real; calling it purely an artifact is misleading. Treat the underlying mechanism rather than the MCV number.

Review questions
Which metabolite most directly helps separate B12 from isolated folate deficiency?

Methylmalonic acid: it rises in B12 deficiency but not typically in isolated folate deficiency; renal function affects interpretation.

Why are reticulocytes low in severe megaloblastic anemia despite a cellular marrow?

DNA synthesis is impaired and many precursors fail before reaching the circulation.

What is the risk of treating possible B12 deficiency with folate alone?

The anemia can improve while B12-related neurologic injury progresses.

10

Anemia treatment: replace, support, and find the cause

Match treatment to the mechanism. Normalizing hemoglobin without identifying why it fell can leave the underlying problem untreated.

Oral and intravenous iron

Oral iron is usually the first replacement strategy for uncomplicated deficiency. Ferrous gluconate, sulfate and fumarate differ in elemental iron per tablet: the course’s examples are approximately 30, 60 and 90 mg, respectively, but formulation strength varies. It also lists iron polysaccharide (150 mg) and heme iron polypeptide/Proferrin (11 mg). Read elemental iron, not just the mass of the salt.

Gastrointestinal effects can include nausea, constipation, diarrhea and dark stools. Absorption depends on formulation, food and interacting medications; vitamin C helps reduce non-heme iron but is not a substitute for adequate dosing and adherence. IV iron is useful when oral therapy is not tolerated, not absorbed, ineffective, or too slow for the clinical need.

An early reticulocyte response can occur around one week, with Hb improvement over the following weeks. Correction takes months; continue long enough to replenish stores, which lag behind Hb. If response is poor, revisit adherence, ongoing bleeding, absorption and the diagnosis. BC iron-deficiency guideline.

B12 and folate replacement: keep the units straight

Daily nutritional requirements are measured in micrograms, while some treatment doses are measured in milligrams. One milligram equals 1000 micrograms. The adult B12 requirement is about 2.4 μg/day; adult folate intake is generally expressed as about 400 μg dietary folate equivalents/day. Treatment doses are much larger than these requirements.

High-dose oral B12, often 1 mg/day, or parenteral replacement can be used depending on cause and severity. Neurologic findings and significant malabsorption require prompt, appropriate treatment. The source’s 100 μg IM loading example is not a universal regimen; contemporary protocols commonly use 1000 μg injections with schedules tailored to presentation. BC B12/folate treatment guideline.

The notes give oral folate replacement examples of 1–5 mg and a common preventive folic-acid dose of 0.4 mg in people planning pregnancy; individual indications alter dosing. Ensure B12 deficiency is addressed. Patients with irreversible B12 malabsorption may need ongoing replacement. Chronic hemolysis increases folate needs; B12 should be replaced when deficient or otherwise indicated, not assumed to be deficient in every hemolytic disorder.

EPO, transfusion and cause-directed therapy

Erythropoiesis-stimulating agents increase red-cell production in selected settings: chronic kidney disease, some chemotherapy-associated anemia and lower-risk MDS. The notes also mention selected antiviral-associated and perioperative indications. Adequate iron availability is essential. Hb below 120 g/L alone is not an indication; thrombotic risks, treatment goals and the underlying disease guide use.

Transfusion supplies functional RBCs quickly when clinically necessary, but does not replace causal treatment. Iron deficiency requires iron and a source investigation; autoimmune hemolysis requires immune-directed therapy; marrow disorders need disease-specific assessment; bleeding requires hemostasis. Chronic transfusion requires monitoring for alloimmunization and iron overload.

Use the exam stem in order

  1. Confirm the pattern: Hb, MCV, reticulocytes, other cell lines and smear.
  2. Name the mechanism: deficient substrate, deficient signaling, marrow disease, loss or destruction.
  3. Find the discriminator: ferritin, DAT, Hb analysis, B12 metabolites, renal function or marrow findings.
  4. Answer the actual request: next investigation, most likely diagnosis and immediate management are different questions.
  5. Check urgency: unstable bleeding, severe symptomatic anemia, MAHA, neutropenic fever and sickle emergencies outrank a routine workup.

The mnemonic maps are memory aids. Explaining why the laboratory pattern follows from the mechanism is what makes similar-looking cases distinguishable.

Review questions
Why continue iron after Hb improves?

Hemoglobin can recover before iron stores are replenished; stopping too early risks recurrent deficiency.

A patient has anemia and low EPO signaling from CKD. What must be adequate for an ESA to work?

Iron and other necessary marrow substrates; the agent cannot create RBCs without the materials.

What is the difference between 1 mg and 1 μg?

One milligram is 1000 micrograms; confusing these units produces a thousandfold error.

Week 10

Bleeding, clotting & transfusion

Follow the platelet plug, the coagulation cascade, and the balance between bleeding and thrombosis.

11

Hemostasis: building and removing a clot

Hemostasis keeps blood inside an injured vessel. Platelets make a temporary plug; coagulation strengthens it with fibrin; natural anticoagulants and fibrinolysis limit the response.

The platelet in one minute

Platelets are small, anucleate fragments of megakaryocyte cytoplasm. They circulate for about 7–10 days; a typical reference count is 150–400 × 109/L (laboratory ranges vary). Their two jobs are to make a plug and provide a phospholipid surface for coagulation reactions.

  • Peripheral zone: membrane glycoproteins mediate adhesion and aggregation; the open canalicular system moves material between the platelet and blood.
  • Sol-gel zone: the cytoskeleton maintains shape and contracts when the platelet activates.
  • Organelle zone: mitochondria, lysosomes and storage granules. Alpha granules contain adhesive/coagulation proteins, including vWF, fibrinogen and factor V. Dense granules supply ADP, ATP, calcium and serotonin.
  • Membrane system: intracellular calcium storage and enzymes involved in prostaglandin production.

Primary hemostasis: three different verbs

Vessel injury → vasoconstriction → adhesion → activation → aggregation
  1. Adhesion = attach to the wall. Injury exposes collagen. Von Willebrand factor (vWF) bridges collagen to platelet GPIb/IX; platelets also have direct collagen receptors.
  2. Activation = recruit and change. Platelets change from discs to spheres with projections, release granules and expose a procoagulant surface. ADP activates P2Y12; newly synthesized thromboxane A2 (TXA2) recruits platelets and promotes vasoconstriction. Calcium rises and GPIIb/IIIa changes into its active form.
  3. Aggregation = attach to one another. Fibrinogen bridges GPIIb/IIIa on adjacent platelets.

TXA2 comes from membrane arachidonic acid through cyclooxygenase and thromboxane synthase; it is synthesized during activation, rather than simply being a stored dense-granule product.

Antiplatelet targets

DrugTargetConsequence
AspirinIrreversible platelet cyclooxygenase-1 inhibitionLess TXA2 production
ClopidogrelP2Y12 ADP receptorLess ADP-driven activation
AbciximabGPIIb/IIIaFibrinogen cannot bridge platelets effectively

Exam correction: aspirin and clopidogrel are not GPIIb/IIIa inhibitors. All three impair primary hemostasis, but at different steps.

Secondary hemostasis: the cell-based model

  1. Initiation: tissue factor exposed at injury binds VIIa. This complex activates IX and X, producing a small amount of thrombin.
  2. Amplification: thrombin activates platelets and factors V, VIII and XI.
  3. Propagation: IXa + VIIIa form tenase, generating Xa. Xa + Va + calcium + platelet phospholipid form prothrombinase, converting prothrombin (II) to thrombin (IIa).
  4. Stabilization: thrombin converts fibrinogen (I) to fibrin and activates XIII. XIIIa cross-links fibrin into a stable mesh.

V and VIII are cofactors, not proteolytic enzymes. The suffix a means activated. Factor XII is important in the laboratory contact pathway but is not required for normal bleeding control in the same way as VIII or IX.

Natural brakes and fibrinolysis

RegulatorWhat it does
Tissue factor pathway inhibitor (TFPI)Limits Xa and the tissue factor–VIIa initiation complex
Activated protein C + protein SInactivate Va and VIIIa, reducing further thrombin generation
AntithrombinInhibits thrombin and activated factors including Xa, IXa and XIa
Tissue plasminogen activator (tPA)Converts plasminogen to plasmin
PlasminBreaks down fibrin; cross-linked fibrin degradation produces D-dimer
PAI-1, alpha-2-antiplasmin, TAFIRestrain tPA, plasmin or fibrinolytic activity, respectively

Thrombin bound to thrombomodulin helps activate protein C: the same enzyme that builds a clot can participate in limiting it. Excess clot formation or inadequate removal causes thrombosis; inadequate clot formation or excessive fibrinolysis causes bleeding.

Review questions
Which receptor binds vWF, and which binds fibrinogen?

GPIb/IX binds vWF for adhesion; activated GPIIb/IIIa binds fibrinogen for aggregation.

Why can factor XIII deficiency bleed despite normal PT and aPTT?

These screening tests end at fibrin formation. Factor XIII acts afterward, cross-linking and stabilizing fibrin.

What is the difference between tenase and prothrombinase?

IXa–VIIIa produces Xa; Xa–Va, with calcium and phospholipid, produces thrombin.

12

Approach to a bleeding patient

First stabilize the patient and control the bleeding source. Then use the bleeding pattern, history, examination and targeted tests to identify the failed part of hemostasis.

First actions and the two bleeding patterns

Airway, breathing and circulation come first. Find and control the source, maintain perfusion and replace deficient blood components when indicated. Correct hypothermia, acidosis and hypocalcemia, which make hemostasis less effective. A serious bleed in a known bleeding disorder is treated promptly with the patient's specialist plan rather than waiting for every investigation.

PatternTypical findingsMain suspects
Primary hemostasisImmediate surface or mucosal bleeding, petechiae, purpura, easy bruising, epistaxis, gum bleeding, heavy mensesPlatelet number or function, vWD, vessel/connective-tissue defects
Secondary hemostasisDeep muscle hematomas, hemarthroses, delayed postoperative bleedingCoagulation-factor deficiency or inhibitor

These are patterns, not absolute rules. Severe vWD can cause deep bleeding because vWF also protects factor VIII.

History: establish a bleeding phenotype

  • Age at onset; spontaneous versus provoked; immediate versus delayed; localized versus multiple sites; duration and severity.
  • Previous hemostatic challenges: dental extraction, operations, trauma, vaccination, circumcision, childbirth and postpartum bleeding. Ask what intervention stopped each bleed.
  • Menstrual history; gastrointestinal or urinary blood; anemia symptoms, iron use and previous transfusions.
  • Prescription and non-prescription drugs: aspirin, NSAIDs, clopidogrel, anticoagulants, some antidepressants and anticonvulsants.
  • Family history, ancestry and consanguinity. An absent family history does not exclude a new mutation or recessive disorder.
  • Liver, kidney, autoimmune and malignant disease; alcohol and nutrition; recent infection.

Inherited disorders include vWD, hemophilia, platelet function defects, rare factor deficiencies, fibrinogen disorders, Ehlers–Danlos syndrome and hereditary hemorrhagic telangiectasia (HHT). Acquired causes include medications, ITP, marrow disease, liver/renal dysfunction and factor or vWF inhibitors. DIC and ordinary vitamin K deficiency are acquired conditions, not typical inherited family-history diagnoses.

Bleeding scores and examination

A bleeding assessment tool (BAT) makes the history reproducible. The ISTH BAT covers 13 domains; commonly used abnormal scores are ≥4 in adult men, ≥6 in adult women and ≥3 in children. MCMDM-1 VWD and the Pediatric Bleeding Questionnaire are related instruments. Their scoring rules differ; use the chosen tool's actual threshold.

Look for pallor, jaundice, bruises, hematomas, telangiectasias, lymphadenopathy, hepatosplenomegaly, joint swelling or restricted movement, and connective-tissue hypermobility. Petechiae are tiny non-blanching spots, purpura are larger, and ecchymoses are bruises. The slides use <2 mm, 3–5 mm and >5 mm respectively, but exact size labels vary between references.

Atypical bruising in a child also requires consideration of trauma and non-accidental injury alongside medical causes; finding a possible bleeding disorder does not settle that assessment.

Initial tests, then specialized tests

Start with CBC and blood film, PT/INR, aPTT, fibrinogen, with thrombin time when indicated. Add liver and renal function, ferritin, calcium, pH and blood grouping according to the presentation.

Second-line testing follows the phenotype: vWF antigen/activity and VIII activity; specific factor assays; mixing and inhibitor studies; platelet aggregation and secretion testing; factor XIII or fibrinolysis assays. Light-transmission aggregometry assesses platelet aggregation; lumiaggregometry measures ATP release; electron microscopy can assess granules.

Normal PT and aPTT do not rule out a bleeding disorder. Platelet disorders, many cases of vWD, factor XIII deficiency, excess fibrinolysis, vessel abnormalities and mild factor deficiencies can have normal screening results.
Review questions
What bleeding pattern suggests a platelet problem?

Immediate mucocutaneous bleeding: petechiae, epistaxis, gum bleeding, heavy menses and easy bruising.

A patient has normal PT/aPTT but convincing lifelong bleeding. Can the workup stop?

No. Consider vWD, platelet dysfunction, factor XIII deficiency, fibrinolytic and vessel/connective-tissue disorders.

Why ask about uneventful surgery or dental work?

Past hemostatic challenges help establish how likely and severe a clinically meaningful bleeding disorder is.

13

Coagulation tests and adult coagulopathy

PT and aPTT are laboratory views of coagulation. Use the abnormal pattern to narrow the differential, then distinguish factor deficiency from inhibition.

What each test measures

TestPathway or targetMeaning
PTVII + X, V, II, IExtrinsic and common pathways; typical reference 9–15 s
INRStandardized PTDesigned for vitamin K antagonist monitoring; about 0.9–1.1 without anticoagulation
aPTTXII, XI, IX, VIII + common pathwayIntrinsic/contact and common pathways; typical reference 25–35 s
Thrombin time (TT)Thrombin added to plasmaProlongs with heparin/direct thrombin inhibitors, low fibrinogen or dysfunctional fibrinogen
Fibrinogen activityFunctional factor IFalls with consumption, severe liver disease, dilution, major bleeding or congenital deficiency
D-dimerBreakdown of cross-linked fibrinSensitive but nonspecific evidence of clot formation and degradation
Anti-XaXa inhibitionAssesses relevant anticoagulant activity using a calibration appropriate to the drug

Reference times depend on the laboratory. Blue-top tubes contain citrate, which binds calcium; the lab adds calcium and reagents back to platelet-poor plasma and measures clotting. PT reagent contains tissue factor; aPTT reagent contains a contact activator and phospholipid without tissue factor.

The four-pattern table

PT/INRaPTTThink of
NormalNormalPlatelet number/function, vWD with preserved VIII, vessel defects, XIII deficiency, fibrinolysis or a mild factor defect
ProlongedNormalVII deficiency/inhibitor; early vitamin K deficiency or warfarin; some liver disease
NormalProlongedVIII/IX/XI deficiency, severe vWD, heparin, specific factor inhibitor, lupus anticoagulant or contact-factor deficiency
ProlongedProlongedX/V/II/I deficiency or inhibitor; DIC; severe liver/vitamin K disease; marked anticoagulant effect; multiple deficiencies, dilution or massive bleeding

Direct oral anticoagulants can affect PT/aPTT variably: a normal result does not reliably exclude a clinically meaningful drug level. Systemic amyloidosis can cause acquired factor X deficiency. A prolonged TT particularly suggests a fibrinogen problem or thrombin inhibition.

The mixing study

Patient plasma + normal plasma, 1:1 → repeat clotting time
Correction → the normal plasma supplied a missing factor
Failure to correct → an inhibitor or interfering anticoagulant remains

Follow with factor levels or inhibitor testing. A factor VIII inhibitor can be time dependent, so incubated studies matter. Partial correction is not a diagnosis: interpret with the laboratory and clinical picture.

Contact-factor trap: XII, prekallikrein and high-molecular-weight kininogen deficiencies can greatly prolong aPTT without causing a bleeding phenotype. In contrast, VIII, IX and XI deficiencies can cause bleeding.

Lupus anticoagulant, liver disease and vitamin K

Lupus anticoagulant is an antiphospholipid antibody phenomenon: it prolongs phospholipid-dependent clotting tests in vitro, yet may be associated with thrombosis in vivo. It does not automatically mean systemic lupus, and a prolonged aPTT does not automatically imply bleeding risk.

Vitamin K is needed for functional II, VII, IX and X, plus proteins C and S. Factor XI is not vitamin K dependent. Poor intake, malabsorption, prolonged antibiotic exposure and newborn physiology can contribute to deficiency. Factor VII has the shortest half-life, so PT often changes first.

Liver disease reduces many procoagulant and anticoagulant proteins. VIII is mainly endothelial-derived and can remain normal or elevated. Because both sides of hemostasis change, INR alone is an incomplete measure of bleeding risk; liver disease can coexist with thrombosis.

In adults, newly recognized bleeding may represent a mild inherited disorder or an acquired inhibitor, particularly acquired hemophilia A. A new VIII inhibitor warrants specialist assessment; simply replacing VIII may not overcome it.

Review questions
Which isolated abnormality fits hemophilia A?

A prolonged aPTT with normal PT/INR, confirmed by low factor VIII activity; mild disease may have a normal screening aPTT.

Why does warfarin affect INR early?

Factor VII falls quickly because of its short half-life; PT is sensitive to the extrinsic pathway.

Why can lupus anticoagulant prolong aPTT yet increase thrombosis risk?

The laboratory assay depends on phospholipid, which the antibody interferes with. Its in-vivo effects are prothrombotic rather than a simple factor deficiency.

14

Hemophilia, von Willebrand disease and platelet dysfunction

These disorders overlap in symptoms but fail at different steps. Identify the missing protein or function, then match treatment to that mechanism.

Hemophilia A and B

A = factor VIII deficiency; B = factor IX deficiency. Both are usually X-linked. Males are commonly affected, but carrier females can also have clinically important low factor levels. About one-third of cases may arise without a known family history.

Think recurrent muscle or joint bleeding, especially knees and ankles, or prolonged bleeding after procedures. Severe disease causes spontaneous bleeding; moderate disease causes occasional spontaneous bleeds and disproportionate traumatic bleeding; mild disease may first appear during surgery. Confirm with factor activity assays, not aPTT alone.

Treatment includes prevention and specialist-guided factor replacement. The course calculation is 1 IU/kg VIII raises VIII activity by approximately 2 percentage points; 1 IU/kg IX raises IX by approximately 1 point, with product/patient variation. DDAVP can help responsive mild A, not B. Tranexamic acid helps selected mucosal bleeding. Inhibitors may require bypassing agents such as recombinant VIIa or activated PCC (FEIBA). Rest, ice, compression and elevation supplement, but do not replace, hemostatic treatment for joint/muscle bleeds.

vWD: quantity, quality and the factor VIII connection

Von Willebrand disease is the most common inherited bleeding disorder. vWF attaches platelets to collagen and carries/protects VIII. It affects all sexes and typically produces epistaxis, bruising, heavy menstrual/postpartum bleeding and procedural bleeding.

TypeDefectKey clue
1Partial quantitative deficiencyAntigen and activity fall roughly together; most common type
2Qualitative defect: 2A, 2B, 2M or 2NFunction is disproportionately low in many subtypes; type 2B can lower platelets; 2N impairs VIII binding
3Nearly absent vWFSevere mucosal and sometimes deep bleeding; low VIII

Test vWF antigen, vWF activity and VIII activity. An activity-to-antigen ratio below about 0.7 supports several qualitative types but does not classify every subtype. Group O people tend to have lower vWF. Stress/inflammation can raise levels, so apparently normal testing may need repetition if the phenotype is convincing.

vWD treatment and acquired platelet dysfunction

Desmopressin (DDAVP) releases stored vWF/VIII and is useful in responsive type 1 disease. Some type 2 patients respond, but many require vWF-containing concentrate. It is ineffective in type 3 and generally contraindicated in type 2B because thrombocytopenia may worsen. Response testing, fluid precautions and sodium monitoring matter. These distinctions refine the slides' simple type 1/type 2–3 split. ASH/ISTH/NHF/WFH vWD management guideline.

Tranexamic acid reduces fibrinolysis and helps mucosal bleeding; hormonal therapy can help heavy menstrual bleeding. Severe bleeding or surgery may require vWF concentrate, with VIII support as indicated.

Uremia causes platelet dysfunction through altered adhesion, signaling and granule responses; the platelet count and screening coagulation times can be normal. Check renal function. Drugs and myeloproliferative disorders are other acquired platelet-function causes.

Inherited platelet function disorders

DisorderStep affected
Bernard–Soulier syndromeGPIb-mediated adhesion; large platelets and thrombocytopenia may accompany it
Glanzmann thrombastheniaGPIIb/IIIa-mediated aggregation
Gray platelet syndromeAlpha-granule abnormality
Storage-pool defectsGranule content/release
Scott syndromeProcoagulant phospholipid exposure
MYH9-related diseasePlatelet number and morphology/function

Many investigated platelet defects remain nonspecific. Exclude medication effects and kidney disease; review count and morphology; use specialist functional testing. Depending on the defect and severity, treatment may involve DDAVP, tranexamic acid, platelets or recombinant VIIa. A Factor First card records the diagnosis, treatment plan and bleeding-centre contacts.

Review questions
Why can vWD prolong aPTT?

Low or dysfunctional vWF reduces factor VIII survival, affecting the intrinsic pathway.

Which vWD subtype may worsen with DDAVP?

Type 2B: increased platelet binding can worsen thrombocytopenia. Type 3 does not respond because there are essentially no stores to release.

Bernard–Soulier versus Glanzmann?

Bernard–Soulier impairs vWF–GPIb adhesion; Glanzmann impairs fibrinogen–GPIIb/IIIa aggregation.

15

Bleeding in children and newborns

Children share adult bleeding mechanisms, but developmental hemostasis, presentation and natural history change the interpretation.

Age changes the reference range

The hemostatic system matures over the first months of life. Newborns, especially premature infants, have lower concentrations of many vitamin K-dependent factors and proteins C and S. PT and aPTT can therefore be longer than adult values without a pathologic bleeding disorder: use age-specific reference ranges.

Concerning bleeding includes prolonged epistaxis, extensive unexplained bruising, gum bleeding or heavy menses, and unusual sites such as the brain, joints or umbilical stump. Dental extraction and circumcision may expose a previously unrecognized disorder. Persistent umbilical bleeding with normal screening times should bring factor XIII deficiency to mind.

The common pediatric patterns

  • ITP: often an otherwise well child aged 2–5 with petechiae after infection and isolated thrombocytopenia. Many recover over the following months. Bleeding severity guides treatment; observation is often appropriate with little or no bleeding.
  • vWD: mucosal bleeding, including nosebleeds and heavy menses. A pediatric bleeding questionnaire helps standardize the history.
  • Hemophilia: deep muscle/joint bleeding often becomes more obvious when mobility increases; boys and bleeding carrier girls require appropriate assessment.
  • Rare factor disorders: XIII, X or fibrinogen abnormalities can present early and severely.

Prevention includes safe activity and protective equipment, good dental care, avoiding aspirin/antiplatelets when inappropriate, and prophylactic hemostatic treatment when indicated. Life-threatening bleeding requires immediate specialist-led replacement and resuscitation; plasma supplies multiple factors, while specific concentrates replace defined deficiencies.

Source detail: the website gives the Pediatric Bleeding Questionnaire cutoff as “>2” in one text and “≥2” in its diagram. The instrument/version and course instructions should determine the cutoff; do not substitute the ISTH pediatric BAT threshold without checking.

Vitamin K deficiency bleeding

TimingTypical context
Early: first 24 hoursMaternal medicines that interfere with vitamin K, including some anticonvulsants
Classical: days 2–7Low neonatal stores and inadequate vitamin K intake/prophylaxis
Late: about 1 week–6 monthsNo birth prophylaxis; exclusive breastfeeding increases risk; cholestasis or malabsorption may contribute

Prevention is vitamin K prophylaxis at birth. The risk is not restricted absolutely to breastfed infants, despite the source chart's wording. CDC: vitamin K deficiency bleeding.

Review questions
Why should neonatal aPTT be compared with an age-specific range?

Coagulation-factor levels differ during developmental hemostasis, particularly in premature infants.

What determines treatment in a child with ITP?

The bleeding phenotype and overall clinical context, rather than platelet count alone.

A newborn has delayed umbilical bleeding and normal PT/aPTT. Which factor is easily missed?

Factor XIII, which stabilizes fibrin after the screening assays have reached their endpoint.

16

Thrombocytopenia and immune thrombocytopenia

A low platelet count can mean reduced production, increased destruction or consumption, splenic pooling, dilution, or simply a counting artifact.

Start with count, film and context

Thrombocytopenia = platelets <150 × 109/L. A useful course severity scheme is 100–149 mild, 50–99 moderate, 10–49 severe, and <10 very severe. Bleeding risk rises as the count falls, but platelet function, site of bleeding, illness and procedures all modify that risk.

  1. Confirm the count and review the peripheral film.
  2. Assess current bleeding, hemodynamic status and other cytopenias.
  3. Look for a time relationship to drugs, heparin, infection, pregnancy or systemic illness.
  4. Use PT/INR, aPTT, fibrinogen, hemolysis markers, renal/liver tests and directed nutritional testing.
  5. Choose additional testing, abdominal imaging or marrow examination from the suspected mechanism.

The mechanism-based differential

MechanismExamplesClue
Reduced productionAplastic anemia, MDS, infiltration/fibrosis, B12/folate deficiency, drugs, viruses, alcohol/toxins, reduced liver thrombopoietinOther abnormal cell lines or marrow findings
Immune destructionITP, drug-dependent antibodiesOften isolated thrombocytopenia
Consumption/thrombosisTTP, HUS, DIC, HIT, preeclampsia/HELLPOrgan injury, thrombosis, hemolysis or abnormal coagulation
SequestrationSplenomegalyOften moderate; treat the cause of the enlarged spleen
DilutionLarge-volume fluid/RBC replacementMajor hemorrhage/resuscitation
PseudothrombocytopeniaEDTA-dependent clumping in the tubeClumps on film; repeat using a suitable alternative tube/method

EDTA pseudothrombocytopenia is an in-vitro artifact, not a bleeding disorder. The analyzer may fail to count clumped platelets correctly. Do not diagnose ITP from a single unverified low automated count.

ITP: mechanism and diagnosis

Immune thrombocytopenia (ITP) combines antibody-mediated platelet clearance, often by splenic macrophages, with impaired production from megakaryocytes. It is a diagnosis of exclusion, typically with isolated platelets <100 × 109/L, otherwise relatively preserved cell lines and normal coagulation times.

Primary ITP has no identified associated condition. Secondary ITP can accompany autoimmune disease, HIV/hepatitis C, lymphoid malignancy or certain drugs. Children often develop it after infection and recover; adults more often have a persistent or relapsing course. Duration terms are newly diagnosed (<3 months), persistent (3–12 months) and chronic (>12 months).

The patient may have no symptoms, petechiae and mucosal bleeding, or rarely critical hemorrhage. Review CBC/film, medication history, infection risks, liver/renal function and pregnancy when relevant. Immunoglobulins, DAT and further testing are selected for the clinical context. Schistocytes, marked hemolysis, organ injury or additional cytopenias should prompt other diagnoses.

ITP management

Observation may be appropriate when bleeding is minimal. When treatment is needed, glucocorticoids are common first-line therapy; IV immunoglobulin can produce a faster, temporary rise. Persistent disease may be treated with thrombopoietin receptor agonists such as romiplostim or eltrombopag, rituximab, splenectomy or selected immunosuppressants including azathioprine.

Platelets are not routine treatment for an isolated low count in ITP: transfused cells may be rapidly destroyed. They can be part of emergency treatment for critical bleeding, alongside treatment of immune destruction. Canadian Blood Services: platelet transfusion.

Review questions
What should happen before labeling an isolated low count as ITP?

Confirm it on blood film and exclude EDTA clumping, drugs, infections and other secondary causes.

Why can ITP reflect both destruction and underproduction?

Antibodies can target circulating platelets and marrow megakaryocytes.

Low platelets plus schistocytes and kidney injury: is ITP the best fit?

No. Investigate thrombotic microangiopathy or DIC urgently.

17

TTP, HUS, HIT and DIC: low platelets can mean clotting

These disorders consume platelets in pathologic clot formation. Distinguish them quickly because their treatments differ and several are emergencies.

Microangiopathic hemolysis: the common clue

Microangiopathic hemolytic anemia (MAHA) occurs when RBCs fragment in damaged small vessels. Expect schistocytes, increased LDH and indirect bilirubin, low haptoglobin and often reticulocytosis. MAHA plus thrombocytopenia suggests a thrombotic microangiopathy (TMA), including TTP and HUS; DIC can also fragment RBCs.

DisorderDistinguishing mechanism/cluePT/aPTT
TTPSevere ADAMTS13 deficiency; neurologic or other ischemic injuryUsually normal
Shiga-toxin HUSDiarrheal illness followed by prominent kidney injuryUsually normal
DICSystemic coagulation activation in a serious underlying illnessOften prolonged
HITPlatelet fall after heparin, often with new thrombosisNot diagnostic; drugs may prolong tests

TTP: do not wait for the pentad

ADAMTS13 normally cuts very large vWF multimers into smaller pieces. Severe deficiency allows vWF-rich platelet microthrombi. Most acquired cases are immune-mediated; congenital deficiency also exists.

The traditional pentad is thrombocytopenia, MAHA, neurologic findings, renal impairment and fever. All five are not required. Unexplained MAHA and thrombocytopenia can be enough to suspect TTP and act urgently. Draw ADAMTS13 activity/inhibitor testing before plasma treatment when feasible; activity <10% strongly supports TTP. A clinical prediction tool such as PLASMIC helps estimate likelihood while results are pending.

Immune TTP treatment involves urgent plasma exchange plus glucocorticoids; rituximab suppresses the antibody response, and caplacizumab blocks vWF–platelet interaction when appropriate. Exchange removes pathogenic antibodies and supplies ADAMTS13. Avoid routine prophylactic platelet transfusion; critical bleeding requires specialist judgment. ISTH diagnosis guideline; 2025 ISTH update.

HUS: kidneys after diarrhea

Hemolytic uremic syndrome classically combines MAHA, thrombocytopenia and acute kidney injury after Shiga-toxin-producing E. coli infection. Toxin damages endothelial cells, particularly in the renal microvasculature. Reduced urine output after a diarrheal illness is a major clue; children are commonly affected.

Care is mainly supportive: careful fluid/electrolyte management, monitoring and dialysis when necessary. In suspected Shiga-toxin infection, antibiotics and antimotility drugs can increase complication risk and are generally avoided. Red-cell transfusion may be needed. Platelet use depends on bleeding/procedure needs, rather than an absolute ban. CDC: E. coli and HUS care.

Not every HUS case is Shiga-toxin-associated: complement-mediated HUS is a different mechanism and requires specialist evaluation. A normal ADAMTS13 result makes severe-deficiency TTP less likely but does not independently prove HUS.

HIT: an immune drug reaction with thrombosis

Platelet factor 4 (PF4) binds heparin; antibodies against the complex activate platelets and promote thrombin generation. The characteristic clue is a >50% platelet fall, commonly 5–10 days after starting heparin, with possible venous or arterial thrombosis. Recent exposure can permit an earlier fall. The count need not fall below 150. Unfractionated heparin carries greater risk than LMWH.

Estimate probability using the 4Ts: magnitude of thrombocytopenia, timing, thrombosis, and other explanations. A PF4/heparin immunoassay detects antibodies; functional testing such as the serotonin-release assay assesses platelet activation. Schistocytes are not a defining HIT finding.

With appropriate clinical suspicion, stop all heparin, including flushes, and start a non-heparin anticoagulant such as argatroban, bivalirudin, fondaparinux or another suitable agent. Do not start warfarin until platelet recovery; early warfarin can worsen thrombosis through protein C depletion. HIT with thrombosis generally requires at least 3 months of anticoagulation. Protamine reverses heparin's anticoagulant effect; it does not treat immune HIT. Thrombosis Canada: HIT.

DIC: systemic coagulation consumes its own supplies

Disseminated intravascular coagulation is widespread coagulation activation caused by an underlying condition, such as sepsis, major trauma, malignancy (especially APL), placental abruption or amniotic-fluid embolism. Microthrombi injure organs while consumption of platelets/factors and altered fibrinolysis promote bleeding.

Typical results are falling platelets, increased D-dimer, prolonged PT (often aPTT), and low or falling fibrinogen. Fibrinogen can be normal or high early because it is an acute-phase reactant. Schistocytes may appear. The ISTH overt-DIC score integrates platelet count, fibrin-related markers, PT prolongation and fibrinogen in the setting of a compatible disorder; a single value does not make the diagnosis.

Treat the cause and support perfusion/organ function. For bleeding, replace the component actually lacking: RBCs, platelets, plasma and fibrinogen concentrate or cryoprecipitate as indicated. The slides' examples are platelets <50 × 109/L, fibrinogen <1 g/L and INR >1.5; these are teaching triggers, not universal targets. Major hemorrhage protocols often require a higher fibrinogen target.

Transfusion distinction: avoid routine platelets in TTP/HIT and avoid unnecessary platelets in HUS; life-threatening bleeding can justify exceptions. DIC with significant bleeding may actively require platelet replacement.
Review questions
What is the missing enzyme in TTP?

ADAMTS13, the protease that cleaves ultra-large vWF multimers.

Platelets fall from 320 to 145 on day 7 of heparin with a new DVT. Is the near-normal count reassuring?

No. The greater-than-50% fall, timing and thrombosis strongly suggest HIT.

Which laboratory pattern helps distinguish DIC from TTP?

DIC often prolongs PT/aPTT and lowers fibrinogen; TTP usually has relatively normal coagulation tests despite MAHA and thrombocytopenia.

18

Transfusion: replace the missing component

Red cells carry oxygen, platelets support primary hemostasis, plasma replaces multiple factors, and concentrates replace selected proteins. Choose by physiology and bleeding context.

Before giving blood

Establish the indication, explain benefits/risks/alternatives and document informed consent when feasible. Emergency care follows the applicable consent process when a patient cannot participate and delay is dangerous. Treat the cause of anemia or coagulopathy as well as its immediate consequences.

  • Group: ABO and RhD typing.
  • Antibody screen: look for clinically significant RBC alloantibodies formed after pregnancy or transfusion.
  • Crossmatch: check compatibility of recipient plasma with donor red cells; an incompatible serologic reaction warns of hemolysis.

O-negative is the usual universal emergency RBC type; AB-positive is the universal ABO/RhD RBC recipient. Emergency use of O-positive RBCs depends on the recipient and blood-bank policy. For plasma, AB is the universal ABO donor because it lacks anti-A/anti-B; RhD is not the defining plasma-compatibility issue. Some emergency protocols use selected group A plasma.

The main components

ProductPurpose and useful numbersCourse storage facts
Packed RBCsAbout 300 mL per unit; one unit commonly raises adult Hb by about 10 g/L. Contains RBCs, residual plasma and preservative.Refrigerated around 4°C; commonly up to 42 days
PlateletsAdult therapeutic dose often about 300–350 mL; pooled or apheresis-derived. Supplies functional platelets.Usually 20–24°C with gentle agitation; product-dependent shelf life, commonly up to 7 days
Frozen plasmaApproximately 250–300 mL per unit; contains all coagulation factors, including fibrinogen.Frozen at or below −18°C; commonly up to 1 year; requires thawing
Fibrinogen concentrateSmall-volume, standardized fibrinogen replacement; viral-reduction manufacturing.Storage and shelf life depend on the licensed product
CryoprecipitateFibrinogen-rich, also VIII, XIII and vWF; roughly 10 mL per unit.Frozen; commonly up to 1 year
Four-factor PCCConcentrated II, VII, IX and X for rapid vitamin K antagonist reversal.Product-specific room-temperature storage; protect as directed

The review lists up to five years for some lyophilized concentrates; exact storage belongs to the product monograph. It also gives conflicting cryoprecipitate fibrinogen numbers. Canadian Blood Services describes 10 units as approximately 3–4 g fibrinogen; do not calculate 4 g from “150 mg ×10.” Canadian Blood Services: components.

Thresholds: remember the setting

  • RBCs: Hb <70 g/L is a common restrictive threshold in stable hospitalized adults. Active hemorrhage, ischemic symptoms, cardiovascular disease and myocardial infarction require individualized thresholds. In non-urgent cases, give one unit and reassess. Ontario transfusion recommendations.
  • Platelets: the course anchors are <10 × 109/L for selected prophylactic settings, about 50 for major surgery/significant bleeding, and about 100 for some critical-site procedures such as neurosurgery. These are context-dependent, not universal transfusion orders.
  • Plasma: use for clinically important multiple-factor deficiency with bleeding or an urgent procedure, including selected DIC/liver disease or massive hemorrhage. Do not treat an isolated mildly elevated INR as an automatic indication.
  • Fibrinogen replacement: for important deficiency during bleeding or congenital deficiency. Cryoprecipitate or concentrate choice and target depend on the setting.
  • PCC + IV vitamin K: urgent warfarin reversal. PCC works quickly; vitamin K sustains correction after the infused factors are cleared.

When transfusion is declined or unnecessary, treat deficiencies with iron, B12 or folate and consider erythropoietic treatment where appropriate; these do not instantly replace oxygen-carrying capacity in major hemorrhage.

Massive hemorrhage

Activate the local massive hemorrhage/transfusion protocol for rapid major blood loss. Early protocolized delivery of RBCs, plasma and platelets prevents delays; fibrinogen replacement and tranexamic acid may be indicated. Warm the patient, monitor ionized calcium, acid–base status and perfusion, and control the bleeding source.

As the situation stabilizes, transition toward laboratory or viscoelastic-test-guided replacement using platelet count, PT/aPTT and fibrinogen. A normal early Hb does not exclude major acute blood loss. Component therapy is central to the supplied course material; availability of whole blood is a local service issue, not a universal rule.

Recognize transfusion reactions

ReactionDistinguishing idea
Acute hemolytic reactionOften ABO incompatibility; fever, pain, hypotension or hemoglobinuria within 24 hours; emergency
Delayed hemolytic reactionAnamnestic RBC alloantibody response days to weeks later; falling Hb/jaundice
Febrile non-hemolytic reactionFever/chills; first exclude hemolysis and contamination
TACOTransfusion-associated circulatory overload: hydrostatic pulmonary edema, often hypertension/fluid overload
TRALITransfusion-related acute lung injury: acute hypoxemia and noncardiogenic pulmonary edema
Allergic reaction/anaphylaxisUrticaria through airway compromise or shock
TA-GVHDDonor lymphocytes attack recipient tissues; fever, rash, diarrhea and cytopenias; irradiation prevents it in at-risk settings
OtherBacterial sepsis, bradykinin-associated hypotension, post-transfusion purpura, alloimmune cytopenias, iron overload after repeated RBCs

For a suspected significant reaction: stop the transfusion, maintain access with appropriate fluid, assess/support the patient, recheck identification and notify the clinical team/blood bank for investigation. Relative rankings such as “most fatal reaction” vary by surveillance period and should not be memorized from this older slide.

Donor testing reduces infectious risk: the source lists HIV, hepatitis B/C, HTLV, West Nile virus, syphilis, bacterial contamination and risk-based Chagas testing. Screening and product processing evolve, and do not remove all risk. Canadian Blood Services: transfusion reactions.

Review questions
Why is universal plasma donor compatibility the reverse of RBC donor compatibility?

For plasma, the important issue is donor antibodies against recipient RBCs. AB plasma contains neither anti-A nor anti-B.

Why give vitamin K as well as PCC for warfarin reversal?

PCC immediately replaces factors; vitamin K restores sustained endogenous production after PCC wears off.

What distinguishes TACO from TRALI mechanistically?

TACO is circulatory volume overload with hydrostatic edema; TRALI is inflammatory/noncardiogenic lung injury.

19

Venous thromboembolism and thrombophilia

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Start with clinical probability, confirm appropriately and treat for a duration matched to recurrence and bleeding risk.

Why venous clots form

Virchow's triad is stasis, endothelial injury and hypercoagulability. Immobility, surgery/trauma, cancer, pregnancy/estrogen exposure, inherited predisposition and previous VTE can contribute. A clot may be provoked by a transient factor, associated with a persistent factor such as active cancer, or unprovoked.

DVT often causes unilateral leg swelling, pain, warmth or erythema. Proximal lower-limb DVT involves popliteal or more proximal veins; distal calf DVT also exists. Mimics include cellulitis, trauma, ruptured Baker cyst, lymphedema and external compression.

PE can cause unexplained dyspnea, pleuritic pain, tachycardia, hemoptysis, syncope or shock. Many patients have no leg symptoms. ECG and chest radiography help assess alternatives and severity; they do not independently exclude PE.

Wells scores: organize pretest probability

For the two-level DVT Wells score, each of the following adds one: active cancer; paralysis/paresis or recent leg immobilization; recent bed rest/major surgery; tenderness along deep veins; entire leg swelling; calf difference >3 cm; unilateral pitting edema; nonvaricose collateral superficial veins; previous DVT. Subtract two if an alternative diagnosis is at least as likely. ≥2 is likely; ≤1 unlikely. Use the exact validated version for its timing definitions.

For two-level PE Wells: DVT signs (3), PE more likely than an alternative (3), heart rate >100 (1.5), recent immobilization/surgery (1.5), previous DVT/PE (1.5), hemoptysis (1), active cancer (1). >4 is likely; ≤4 unlikely.

These tools guide testing; a score does not itself diagnose or exclude a clot.

D-dimer and imaging

Appropriate low/unlikely probability → sensitive D-dimer
Negative at the validated threshold → VTE can be excluded in that pathway
Positive, or higher clinical probability → imaging

D-dimer rises in cancer, pregnancy, inflammation, infection, trauma, surgery, increasing age and DIC. A positive result is nonspecific; it is not meaningless. It tells you that a rule-out strategy has not excluded VTE. Do not use it alone to exclude high-probability disease.

Compression ultrasound is the standard first test for suspected leg DVT. If a limited initial scan is negative but suspicion persists, repeat or additional testing may be needed; the source's instruction to repeat “if positive” is misleading. CT pulmonary angiography is commonly used for PE; ventilation/perfusion scanning is an alternative in selected patients. Invasive venography and pulmonary angiography are historical reference standards, not routine first tests. Thrombosis Canada: DVT diagnosis; BC VTE guideline.

Treatment, duration and prevention

Anticoagulants prevent extension and new clotting while endogenous mechanisms clear the clot. Suitable options include DOACs, LMWH and warfarin. Pregnancy usually favors LMWH; active cancer requires attention to tumor site, bleeding risk, interactions and ongoing treatment. Hemodynamic instability, hypoxemia or high-risk features may require admission. Many stable patients can be treated as outpatients.

Thrombolysis or procedural reperfusion is reserved for selected severe presentations, especially high-risk PE with shock, because bleeding risk is substantial. Mobilization is encouraged as appropriate; elevation or compression may relieve symptoms. Do not automatically add NSAIDs to an anticoagulated patient because they can increase bleeding.

ContextDuration principle
Major transient provoking factorUsually at least 3 months for treated proximal DVT/PE
Unprovoked or persistent riskInitial treatment followed by a recurrence-versus-bleeding assessment; extended treatment is often appropriate
Active cancerContinue while cancer-associated risk remains, with periodic review

The slide's “one month after injury” confuses prophylaxis with treatment; “idiopathic = lifelong” is too absolute. Duration is individualized. HERDOO2 can identify some lower-risk women after a first unprovoked VTE: leg hyperpigmentation/edema/redness, D-dimer, obesity and older age. It is not a general stopping rule for all patients. Thrombosis Canada: duration.

Prevention uses early mobilization and risk-appropriate mechanical/pharmacologic prophylaxis. Extended prophylaxis may follow high-risk orthopedic or cancer operations; its duration is different from treatment of an established VTE.

Thrombophilia: too much accelerator or too little brake

ConditionMechanism
Factor V LeidenFactor V resists activated protein C inactivation
Prothrombin G20210A variantHigher prothrombin tendency
Protein C or S deficiencyLess inactivation of Va and VIIIa
Antithrombin deficiencyLess inhibition of thrombin/Xa and other activated factors
Antiphospholipid syndromeAcquired immune thrombophilia; can cause venous/arterial thrombosis and pregnancy morbidity

Inherited thrombophilias often show dominant familial patterns, with risk modified by heterozygosity versus homozygosity and acquired exposures. The source's exact prevalence and relative-risk estimates are population-dependent; do not treat them as universal values.

A young patient, recurrent/unusual-site thrombosis or a strong family history can prompt specialist consideration, but testing is not automatically useful after every unprovoked VTE. Order when results could change management; acute thrombosis and anticoagulants can distort some assays. BC guideline: selective thrombophilia testing.

Review questions
What are Virchow's three contributors?

Stasis, endothelial injury and hypercoagulability.

Can a positive D-dimer diagnose PE?

No. It is nonspecific and must be interpreted through a clinical-probability and imaging pathway.

Why is three months of VTE treatment different from postoperative prophylaxis?

Treatment addresses an established clot and recurrence risk; prophylaxis prevents a first clot during a temporary high-risk period.

20

Anticoagulants: mechanisms, monitoring and reversal

Indirect drugs use antithrombin. Direct drugs inhibit an activated factor themselves. Warfarin reduces production of functional vitamin K-dependent proteins.

The antithrombin-dependent injectables

DrugMechanismPractical features
Unfractionated heparin (UFH)Antithrombin-mediated IIa and Xa inhibition, plus other activated factors. Thrombin inhibition needs a long enough chain to bridge thrombin and antithrombin.IV or SC; short, dose-dependent half-life around 60–90 min; useful when rapid adjustment or severe renal dysfunction matters; monitor aPTT or anti-Xa.
LMWH: enoxaparin, dalteparin, tinzaparin, nadroparinAntithrombin-mediated Xa > IIa inhibitionSC, more predictable, often outpatient; half-life roughly 3–6 h; renal clearance is important; no routine aPTT monitoring.
FondaparinuxSynthetic pentasaccharide; antithrombin-mediated Xa inhibition onlySC; half-life about 17–21 h; renal clearance; avoid in severe renal impairment according to product guidance.

Mechanism correction: the slide table reverses key targets. The pentasaccharide supports anti-Xa activity; a chain of at least about 18 sugar units is needed to bridge antithrombin to thrombin. UFH inhibits IIa and Xa; LMWH favors Xa; fondaparinux inhibits Xa.

UFH can cause bleeding, HIT and osteoporosis with prolonged exposure; HIT is less common with LMWH. UFH is used in thrombosis treatment and selected dialysis, bypass, ECMO or coronary settings. LMWH is important in VTE treatment/prophylaxis, pregnancy and some cancer-associated thrombosis. If monitoring LMWH/fondaparinux is needed, use appropriately calibrated anti-Xa assays.

Monitoring numbers in the notes: therapeutic UFH is often adjusted to an institution-calibrated aPTT (historically about 1.5–2.5 times baseline) or anti-Xa about 0.3–0.7 IU/mL. An absolute aPTT of 60–80 seconds is not transferable across all reagents. LMWH and fondaparinux usually need no routine level measurement; aPTT is unsuitable for quantifying them.

Warfarin and the DOACs

AgentMechanismMonitoring and cautions
WarfarinInhibits VKORC1, reducing functional II, VII, IX, X, C and SPT/INR; usual target often 2–3, but indication-specific. Many food/drug interactions, delayed effect, narrow therapeutic range.
Apixaban, rivaroxaban, edoxabanDirect Xa inhibitionNo routine coagulation-test dose titration; assess renal/hepatic function, interactions and adherence.
DabigatranDirect thrombin (IIa) inhibitionRenal function is especially important; no routine aPTT dose titration.

Warfarin's half-life is about 36–42 hours, but its effect also depends on the turnover of clotting factors. It remains useful for mechanical valves and selected other indications. It is generally avoided in pregnancy; specialist exceptions require individualized management.

DOACs have rapid onset, predictable effects, fixed regimens for defined indications and fewer interactions than warfarin. Typical half-lives are around 7–18 hours, prolonged by organ dysfunction. P-glycoprotein interactions matter, and strong CYP3A4 inhibitors/inducers affect some Xa drugs. “No routine INR monitoring” does not mean “no follow-up.”

Warfarin INR checks are frequent during initiation and after interacting drugs or dose changes, then spaced when stable. The source cites every 1–2 days initially and every 4–6 weeks when stable; actual follow-up is individualized. Early protein C reduction is why selected acute thrombosis regimens require overlap with a faster anticoagulant.

IV direct thrombin inhibitors

Bivalirudin binds thrombin and can inhibit clot-bound thrombin; it is cleared mainly by enzymatic metabolism with a renal contribution. Argatroban is mainly hepatically cleared. Both have short half-lives (roughly 25–45 minutes in normal organ function), are given IV and are commonly monitored with aPTT in appropriate settings.

They are useful for selected coronary procedures or HIT. Renal dysfunction changes bivalirudin handling; hepatic dysfunction particularly changes argatroban handling. They do not share one universal “avoid all kidney or liver disease” rule. Argatroban also raises INR, complicating transition to warfarin. Older hirudins such as lepirudin/desirudin appear in the slides; their properties should not be generalized to all modern direct thrombin inhibitors.

Reversal: match the antidote to the drug

DrugReversal concept
UFHProtamine neutralizes heparin; dose depends on heparin received recently. The teaching relation is 1 mg protamine per 100 units UFH.
LMWHProtamine provides partial reversal; anti-Xa activity is incompletely reversed.
FondaparinuxProtamine does not reverse it; no established specific antidote. Specialist hemostatic strategies may be considered in severe bleeding.
WarfarinFor urgent major bleeding: four-factor PCC plus IV vitamin K.
DabigatranIdarucizumab binds dabigatran.
Apixaban/rivaroxabanAndexanet alfa for eligible life-threatening/uncontrolled bleeding where available; PCC is used in appropriate local pathways.
IV direct thrombin inhibitorsStop infusion and provide supportive/source-control care; short half-life helps when clearance is normal.

The older slides' “andexanet pending approval” wording is outdated for Canada; availability and indications still depend on jurisdiction and service. It is not a routine reversal agent for every heparin or every Xa drug. Thrombosis Canada: DOAC bleeding; UFH, LMWH and fondaparinux guide.

Stopping before a procedure

Elective interruption depends on the procedure's bleeding risk, dose, renal function, thrombotic indication and anesthetic plan. Useful course anchors are IV UFH about 4–6 hours, therapeutic LMWH often about 24 hours, and warfarin often 5 days. Fondaparinux and DOAC timing requires drug- and renal-function-specific planning; short slide rules should not be used as universal perioperative instructions.

Active major bleeding is a major contraindication to anticoagulation, but thrombocytopenia or recent surgery requires context, not a blanket ban: HIT itself requires anticoagulation despite the falling platelet count. Reversal never replaces resuscitation, local hemostasis and treatment of the bleeding source.

Review questions
Which agents need antithrombin?

UFH, LMWH and fondaparinux. Direct Xa/thrombin inhibitors do not.

What reverses dabigatran?

Idarucizumab; vitamin K does not reverse it.

Why is fondaparinux not simply a stronger LMWH?

It is a synthetic pentasaccharide that inhibits Xa via antithrombin, without the chain length needed for thrombin bridging.

21

Quality improvement: change a process and measure it

Quality improvement (QI) applies knowledge to make a real local system perform better. The missing step is often understanding the process before choosing a solution.

Eight steps, one repeated learning cycle

  1. Identify the problem: describe the gap in actual performance.
  2. Set a SMART aim: specific, measurable, achievable, relevant and time-bound.
  3. Understand the causes: observe the process and investigate why the gap exists.
  4. Generate and select solutions: match the intervention to a cause.
  5. Choose measures: decide how success and unintended effects will be detected.
  6. Try a small change: begin at a scale that permits rapid learning.
  7. Study the results: compare what happened with what was predicted.
  8. Act: adapt, adopt or abandon the change; sustain useful gains and repeat.

This fits a Plan–Do–Study–Act cycle. A SMART example: “Increase appropriate pretransfusion antibody screening from 80% to 95% in this clinic within 12 weeks.” The figures are illustrative, not an actual study result.

Choose a tool for the question

ToolPurpose
Fishbone/Ishikawa diagramOrganize possible causes under categories such as people, process, equipment and environment
Process mapShow the sequence, inputs, handoffs, decisions and outputs; locate delays or failure points
Hierarchy of effectivenessFavor reliable system redesign/constraints when suitable; education and reminders alone depend more on individual memory
Run chartPlot performance over time to distinguish sustained patterns from a single good or bad day

A fishbone diagram generates hypotheses; it does not by itself prove that each proposed cause is responsible. Test assumptions with observation and data.

Outcome, process and balancing measures

  • Outcome: the result that matters—e.g., rate of preventable transfusion delays.
  • Process: whether the intended work happened—e.g., proportion screened before a planned transfusion.
  • Balancing: unintended consequences—e.g., extra testing, cost or longer appointment time.

QI often uses small, frequent samples sufficient for the next decision. Context and variation are informative; an outlier may reveal a special cause worth studying.

QI versus conventional research

Research usually asks whether an intervention creates generalizable knowledge; QI usually asks how to improve a particular system using available knowledge. Research may hold an intervention fixed and control context; QI often adapts sequentially and examines context closely.

These are tendencies, not absolute boundaries. Research does not automatically discard outliers, and QI is not exempt from careful design, ethics or measurement. The purpose and methods determine the appropriate oversight.

Review questions
Which measure detects an intervention making another part of care worse?

A balancing measure.

Why is root-cause analysis before solution selection useful?

It connects the proposed change to the actual process failure, rather than an assumed cause.

What makes an aim SMART?

It states a specific and measurable target that is achievable, relevant and time-bound.

22

Critical appraisal and trial interpretation

Evidence-based medicine combines research evidence, clinical expertise and patient values. Appraisal asks whether a result is trustworthy, clinically important and applicable.

Research designs and equipoise

Descriptive work characterizes what happens: case reports/series, descriptive or correlational studies and qualitative interviews. Analytical observational studies include cohorts, case–control and cross-sectional designs. Experimental studies assign an intervention: randomized trials, nonrandomized trials and community-level trials.

Clinical equipoise is honest uncertainty in the expert community about the comparative merits of the trial interventions. It does not require proving that nobody knows anything. A trial must also consider whether an established effective treatment is being withheld without ethical justification.

Chance, bias and confounding

ProblemMeaningHow to address it
ChanceRandom sampling variationAdequate sample size; quantify uncertainty with confidence intervals
BiasSystematic error in design, conduct, measurement or analysisAppropriate allocation, concealment, masking, follow-up and prespecified analysis
ConfoundingAn exposure–outcome association is mixed with effects of another variableRandomization or suitable design/analysis adjustment

A classic confounder is related to the exposure, is a risk factor for the outcome, and is not an intermediate on the causal pathway. Randomization balances factors in expectation; it does not guarantee perfect equality in one small sample.

Allocation concealment prevents foreknowledge during enrollment. Blinding limits behavior or assessment changes after allocation. Open-label means allocation is known. “Single,” “double” and “triple” blind can be ambiguous: specify whether patients, clinicians, outcome assessors or analysts were masked. Unblinding discloses assignment.

Trial phases and the protocol

PhaseMain purposeCourse scale
ISafety, dose and pharmacologyOften tens of participants
IIPreliminary efficacy and further safetyOften dozens to a few hundred
IIIComparative benefit/risk against standard treatment or suitable controlOften hundreds to thousands
IVPostmarketing effectiveness and uncommon/late adverse effectsOften larger populations

The source's specific ranges (10–30, 50–100, 100–1000, >1000) are teaching examples, not definitions. Phase is determined by purpose, not participant count.

A protocol specifies rationale, objectives, design/schema, eligibility, enrollment and randomization, treatments, primary/secondary endpoints, clinical assessments, sample size/power and analysis, data collection, safety monitoring, and plain-language consent materials.

Superiority, non-inferiority and equivalence

  • Superiority: seeks evidence that one strategy is better.
  • Non-inferiority: asks whether a new strategy is no worse than the comparator by more than a prespecified clinically acceptable margin, delta. It may offer benefits in toxicity, convenience or cost.
  • Equivalence: seeks to place the difference within prespecified lower and upper clinically unimportant limits.

A nonsignificant superiority result does not establish equivalence or non-inferiority. It may simply be imprecise. Read the confidence interval relative to the relevant margin and confirm that the margin was justified before seeing the data.

ITT, per-protocol and endpoints

Intention-to-treat (ITT) analyzes participants in their randomized groups, even when adherence changes. It preserves the main benefit of randomization, but missing outcomes still require appropriate handling. Per-protocol analysis focuses on participants who sufficiently followed the protocol; excluding nonadherent participants can reintroduce bias.

ITT is often conservative for superiority, but not automatically so for non-inferiority: nonadherence may make groups look artificially similar. Comparing appropriate ITT and per-protocol analyses is therefore useful in a non-inferiority trial.

The primary endpoint drives the main hypothesis and power calculation. A composite endpoint counts any of several component events; check whether a common but less important component drives the result. Components are not necessarily clinically equal just because the analysis counts each event. Death and other competing events require thoughtful handling rather than automatic exclusion. Secondary and subgroup findings should be interpreted with multiplicity, prespecification and interaction testing in mind.

Errors, power and uncertainty

  • Type I error (alpha): false positive—rejecting a true null hypothesis.
  • Type II error (beta): false negative—failing to detect a specified true effect.
  • Power = 1 − beta: probability of detecting that effect under the design assumptions.
  • p-value: under the null/model assumptions, the probability of results at least as incompatible with the null as those observed. It is not the probability that the null is true.
  • 95% confidence interval: conveys effect size and precision; the interval procedure covers the true parameter in 95% of repeated samples under its assumptions.

Statistical significance is not clinical importance. A large trial can detect a tiny difference, while a small trial can miss an important one. A one-sided test examines a prespecified direction; a two-sided test allows evidence in either direction. Choose the approach before seeing results.

Treatment-effect calculations

MeasureFormula
Absolute risk (AR)Events / participants in that group
Absolute risk reduction (ARR)Control risk − treatment risk
Relative risk (RR)Treatment risk / control risk
Relative risk reduction (RRR)1 − RR
Number needed to treat (NNT)1 / ARR, with ARR as a proportion; round up for whole people

Worked example: over one year, bad outcomes occur in 20% of controls and 15% of treated participants. ARR = 5 percentage points = 0.05; RR = 0.75; RRR = 25%; NNT = 20 over one year. Always state the outcome and time horizon. Relative reduction alone can exaggerate the apparent benefit when baseline risk is low.

Review questions
A superiority trial has p = 0.20. Does that prove equal treatments?

No. Failure to show a difference is not proof of equivalence; inspect precision and a prespecified equivalence/non-inferiority design if relevant.

A treatment lowers event risk from 10% to 8%. What are ARR and NNT?

ARR is 2 percentage points, or 0.02. NNT is 50 over the study's stated time horizon.

Why might per-protocol analysis lose randomization's protection?

People excluded for nonadherence may differ systematically in prognosis, adverse effects or other characteristics.

Week 11

White cells & marrow disorders

Distinguish reactive changes from clonal disease, then connect cell lineage to diagnosis and treatment.

23

White cells and innate immunity

Start with the job of each white cell. The same family tree explains the CBC differential and the names of blood cancers.

A visible source gap

The website lists Innate Immunity and WBCs but supplies no lecture note. This section covers the immune-cell basics present in the review slides; it cannot reconstruct the missing lecture's full objectives.

The two branches

A hematopoietic stem cell gives rise to myeloid and lymphoid descendants. Myeloid cells include red cells, megakaryocytes/platelets, granulocytes and monocytes. Lymphoid cells include B cells, T cells and natural killer (NK) cells.

Innate immunity responds rapidly to shared microbial or danger patterns. Adaptive immunity uses antigen-specific B- and T-cell receptors and develops memory. NK cells are lymphoid by lineage but innate by function.

Know every cell in the differential

CellMain role and identifying clueWhen increased
NeutrophilMost numerous circulating white cell; multilobed nucleus; phagocytoses bacteria and participates in acute inflammation.Bacterial infection, inflammation, stress, drugs or a myeloid neoplasm.
EosinophilBilobed nucleus with orange-red granules; parasite defence and allergic inflammation.Allergy, parasites, drug reaction, selected inflammatory or clonal diseases.
BasophilDark blue granules; immediate hypersensitivity mediators.Allergy/drugs, hypothyroidism or a myeloid neoplasm, especially CML.
MonocyteCirculating phagocyte precursor; can become tissue macrophages or some dendritic cells.Chronic infection/inflammation or a myeloid neoplasm.
LymphocyteB cells make antibodies through plasma-cell differentiation; T cells coordinate responses or kill infected cells.Often viral infection; persistent clonal lymphocytosis raises CLL/other lymphoproliferative disease.

A few mechanistic links

Dendritic cells link innate sensing to T-cell activation by presenting antigen. The slide's macrophage shorthand is M1 = inflammatory and M2 = repair/anti-inflammatory; actual macrophage states are more varied.

NK cells detect a balance of activating and inhibitory signals. Reduced self-MHC class I can remove inhibition, helping them target infected or abnormal cells. T-cell cytotoxicity instead depends on antigen-specific recognition.

Myeloid precursor arrested early → AML. Promyelocyte arrest with PML::RARA → APL. Mature clonal granulocyte expansion → CML. Lymphoid blasts → ALL. Mature clonal B-cell accumulation → CLL. Antibody-producing plasma-cell clone → myeloma.

Review questions
Which lymphoid cell belongs to innate immunity?

The natural killer (NK) cell.

Why can a myeloproliferative neoplasm affect red cells and platelets as well as neutrophils?

All three derive from the myeloid branch of hematopoiesis.

24

Approach to leukocytosis

A high total white count is a starting point. Identify the increased lineage, inspect maturity, and decide whether the response is reactive or clonal.

Read the count in context

The course uses a typical adult WBC reference interval of 4–10 × 109/L; age and laboratory intervals matter. Obtain a CBC with differential and a blood film. Ask about fever, exposures, medications, smoking, weight loss, sweats and duration. Examine vital signs, lymph nodes, spleen and gums.

Blasts, cytopenias, rapid clinical decline or symptoms of leukostasis warrant urgent hematology assessment. A high count alone is not a diagnosis of leukemia, and leukemia can occur with a normal or low total WBC.

Reactive versus neoplastic clues

Reactive patternClonal/myeloid neoplasm pattern
Compatible infection, inflammation, tissue injury or drug exposure.Persistent unexplained counts, splenomegaly, constitutional symptoms.
Neutrophil left shift: more immature forms such as bands. Toxic granulation, cytoplasmic vacuoles and Döhle bodies favour inflammation.Broad spectrum of immature myeloid cells; basophilia/eosinophilia; blasts or other abnormal morphology.
No sustained clonal population demonstrated.Clonal cytogenetic or molecular finding, such as BCR::ABL1.

The slides flag WBC >30 as concerning and >100 as especially concerning. These are warning patterns, not absolute boundaries: severe reactive leukocytosis exists, and serious leukemia may have lower counts.

Why neutrophils rise

  • Increased reactive production: infection, inflammatory/autoimmune disease, burns, myocardial infarction or other tissue necrosis, trauma, surgery, severe hemolysis, malignancy and metabolic stress such as diabetic ketoacidosis.
  • Drugs/physiology: glucocorticoids, lithium, granulocyte colony-stimulating factor (G-CSF), smoking and pregnancy.
  • Redistribution: exercise, seizures, epinephrine, beta-agonists and acute stress detach marginated neutrophils from vessel walls. Hyposplenism or splenectomy reduces splenic pooling/clearance.
  • Clonal production: CML, other myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML) or marrow infiltration. Hereditary neutrophilia and leukocyte adhesion deficiency are uncommon alternatives.

CML is the review's key malignant neutrophilia: granulocytes at different maturation stages, basophilia, often eosinophilia and a BCR::ABL1 fusion.

Other lineages: keep the differential broad

  • Eosinophilia: absolute eosinophil count >0.5 × 109/L. Consider asthma/eczema, drug reactions including penicillins, helminths, eosinophilic lung disease, eosinophilic granulomatosis with polyangiitis, vasculitis and other connective-tissue disease.
  • Basophilia: growth-factor drugs, hypersensitivity and hypothyroidism; persistent marked basophilia warrants evaluation for CML/other myeloid disease.
  • Monocytosis: TB, endocarditis, malaria/rickettsial infection, inflammatory bowel disease, SLE and post-splenectomy states; persistence can suggest CMML.
  • Lymphocytosis: viral infection is common. EBV mononucleosis is a classic young-person vignette; reactive lymphocytes may have abundant cytoplasm that moulds around red cells. CMV, hepatitis viruses, HIV and other infections also matter.

Workup follows the suspected cause

Repeat a transient abnormality after recovery. Infection testing is directed by history: EBV testing, CMV, HIV, hepatitis, TB or toxoplasma when appropriate. The heterophile/Monospot test can support mononucleosis but has limitations early in illness and in children.

Use chest imaging, abdominal ultrasound, metabolic/autoimmune testing and cancer assessment selectively. Persistent unexplained lymphocytosis, particularly in an older adult or after 4–6 weeks, may require flow cytometry for clonality. A suspected myeloid neoplasm may require BCR::ABL1 testing by PCR/FISH/karyotype, JAK2 testing and other sequencing. Treat the underlying reactive cause, rather than the count alone.

Review questions
A neutrophil rise with toxic granules and a recent bacterial infection suggests what?

Reactive neutrophilia. The film and clinical context support an inflammatory marrow response.

Persistent neutrophilia, basophilia and splenomegaly should trigger which defining test?

Testing for BCR::ABL1, the fusion associated with the Philadelphia chromosome in CML.

25

Leukopenia and febrile neutropenia

When white cells are low, the absolute neutrophil count predicts an important part of infection risk. Fever changes the urgency immediately.

Calculate and grade the ANC

ANC = total WBC × (neutrophil fraction + band fraction). For WBC 2.0 and neutrophils/bands 20%, ANC = 0.4 × 109/L.

ANC, ×109/LCourse category
1.0–1.5Mild neutropenia
0.5–0.99Moderate
<0.5Severe

Duration, depth, mucosal injury and other immune defects also affect risk. A stable constitutional low count can be benign; investigate the individual clinical context instead of assuming that every low ANC has the same implication.

Causes: production, destruction or pooling

  • Infections: EBV, CMV, hepatitis A/B/C, HIV, influenza; severe bacterial sepsis, mycobacteria, Salmonella, Brucella or rickettsial infection.
  • Drugs/toxins: chemotherapy, radiation, clozapine, antithyroid drugs, antibiotics such as trimethoprim-sulfamethoxazole or dapsone, and antiepileptics.
  • Immune: autoimmune neutropenia, SLE or rheumatoid arthritis. Felty syndrome links rheumatoid arthritis, neutropenia and splenomegaly.
  • Nutrition: vitamin B12, folate or copper deficiency; malnutrition.
  • Marrow: MDS, AML, aplasia, lymphoma or metastatic tumour replacing marrow.
  • Sequestration: an enlarged spleen.
  • Congenital: cyclic neutropenia, severe congenital/Kostmann neutropenia, Chediak–Higashi, Shwachman–Diamond and Barth syndromes.

Recognize febrile neutropenia

The examination fever definition is one oral temperature ≥38.3°C, or ≥38.0°C sustained for at least one hour. The usual oncology definition pairs this with ANC <0.5 × 109/L, or a count expected to fall below that level shortly. This is more specific than simply combining fever with the general ANC <1.5 definition. Fever can be the only infection sign. COSTaRS fever-with-neutropenia guide.

The immediate sequence

  1. Stabilize: airway, breathing and circulation; fluids when needed and oxygen for hypoxemia.
  2. Look and sample promptly: CBC/differential, renal/electrolyte/liver tests, blood cultures including line cultures as relevant, and urine/other targeted cultures. Chest imaging follows respiratory findings or local protocol.
  3. Examine likely entry sites: mouth, sinuses, lungs, abdomen, skin, catheter sites and perineal region by inspection. Avoid digital rectal examination.
  4. Start empiric antipseudomonal antibiotics urgently: the notes name piperacillin–tazobactam or a carbapenem; cefepime is another protocol-dependent option. Do not delay treatment for tests that cannot be obtained promptly.
  5. Add vancomycin selectively: instability or suspected catheter/skin infection and other appropriate gram-positive indications; it is not routine for every case.

Recognize gram-negative threats such as E. coli, Pseudomonas and Klebsiella; gram-positive staphylococci/streptococci/enterococci; HSV/CMV/VZV reactivation; and Candida, Aspergillus or mucormycosis with prolonged or profound immunosuppression. eviQ immediate management.

Review questions
WBC 1.5 with 20% neutrophils: what is the ANC?

0.3 × 10^9/L, which is severe neutropenia.

Should antibiotics wait for culture results?

No. Obtain cultures promptly if feasible, then start empiric treatment urgently; results are used to refine therapy later.

26

Specialized hematology testing

Morphology shows what cells look like; flow identifies their antigen pattern; chromosome and molecular tests identify the clone and its biology.

Aspirate versus core

A marrow aspirate provides individual cells for morphology, flow cytometry, cytogenetics and molecular work. A core biopsy preserves architecture, estimates cellularity and shows fibrosis or infiltration.

The posterior iliac crest near the posterior superior iliac spine is the standard sampling site. Sternal aspiration and infant tibial sampling are special procedures; never take a sternal or tibial core biopsy. The notes also exclude skull/rib sampling. These are anatomy principles, not instructions to perform the procedure.

What normal marrow looks like

Normal marrow contains erythroid and myeloid cells at successive maturation stages, without dysplasia. The course gives a myeloid-to-erythroid ratio around 1:1–3:1. Cellularity roughly follows 100 minus age as a percentage, a teaching estimate with a broad normal range. A subcortical acellular zone can occur.

Hypercellular means more blood-forming cells than expected for age; hypocellular means fewer. A hypocellular aspirate can be misleading if diluted with blood, so the core and specimen quality matter.

Flow cytometry in one minute

Cells in suspension pass a laser. Forward scatter approximates size; side scatter reflects internal complexity/granules. Fluorescent antibodies detect surface or intracellular antigens. The combined expression pattern is the immunophenotype.

Fresh blood, marrow, cerebrospinal fluid and other fluids can be tested; tissue such as a node must be disaggregated. The notes emphasize fresh specimens, ideally processed within 24 hours according to laboratory requirements.

  • B-lineage markers include CD19, CD20 and CD79a.
  • T-lineage markers include CD3, CD5 and CD7; CD4 denotes helper and CD8 cytotoxic subsets.
  • Myeloperoxidase (MPO) supports myeloid differentiation; terminal deoxynucleotidyl transferase (TdT) supports an immature lymphoid phenotype in context.
  • Light-chain restriction supports a clonal B-cell population, rather than the mixed kappa/lambda population of a reactive response.

Genetics answers a different question

Karyotyping surveys chromosome number and large structural changes. FISH uses fluorescent probes for specific chromosome rearrangements/deletions. PCR detects or quantifies a target sequence; quantitative BCR::ABL1 PCR is useful in CML monitoring. Next-generation sequencing tests many genes for mutations.

These tests establish disease subtype, predict prognosis, guide targeted treatment and sometimes track residual disease. A deletion such as del(5q), a translocation such as t(9;22), and a point mutation such as JAK2 V617F are different kinds of change. Interpret genetics alongside morphology, flow, counts and clinical findings.

Review questions
Why obtain both an aspirate and core biopsy?

The aspirate shows individual cells and supplies fresh material for ancillary tests; the core preserves marrow architecture, cellularity and fibrosis.

What do forward and side scatter represent?

Forward scatter approximates cell size; side scatter reflects granularity/internal complexity.

27

Acute leukemia: AML, ALL and children

Acute leukemia is a malignant accumulation of immature cells that displaces normal marrow. Marrow failure and early emergencies explain the presentation.

Recognize the presentation

Loss of normal marrow function produces anemia → fatigue/pallor, thrombocytopenia → bruising/bleeding, and neutropenia or ineffective white cells → fever/infection. Bone pain, sternal tenderness, nodes or hepatosplenomegaly may accompany it.

Leukemia can infiltrate gums, skin (leukemia cutis), tissues behind the eyes or other sites. A mass of myeloid blasts outside marrow is a myeloid sarcoma. Risk factors taught include older age, prior MDS/MPN, smoking, benzene, previous cytotoxic drugs/radiation and predisposition syndromes such as Down, Fanconi anemia, Bloom and ataxia telangiectasia.

AML versus ALL

FeatureAcute myeloid leukemiaAcute lymphoblastic leukemia
CellMyeloid blast; MPO may be positive. Auer rods support AML but are not present in every case.B- or T-lineage lymphoblast; typically TdT-positive, without Auer rods.
Typical age clueMost adult acute leukemia; also occurs in children.Most childhood acute leukemia; also occurs in adults. Most childhood ALL is B-lineage.
Extra cluesGingival/skin involvement in some monocytic variants; APL has especially high bleeding risk.Nodes, bone pain and hepatosplenomegaly; T-ALL can have a mediastinal mass. CNS/testes are sanctuary sites.
Broad treatment structureInduction, then consolidation chemotherapy and/or selected allogeneic stem-cell transplantation.Induction, consolidation/intensification, maintenance and CNS-directed treatment.

The course uses approximate epidemiology anchors: AML accounts for about 80% of adult acute leukemia, ALL for about 80% of childhood leukemia, and about 80% of childhood ALL is precursor B-lineage. These are teaching proportions rather than universal population constants. Older FAB labels include M3 for APL and M4/M5 for myelomonocytic/monocytic AML; genetics now drives much of classification.

What confirms it?

Examine blood and marrow morphology, immunophenotype, cytogenetics and molecular findings. The traditional teaching threshold is ≥20% blasts in blood or marrow, not necessarily >20% in marrow alone. AML-defining genetic abnormalities can establish AML below 20%; exact requirements differ between modern classification systems. WHO classification update.

Order CBC/film, coagulation studies including fibrinogen and D-dimer, and tumour-lysis tests: potassium, phosphate, calcium, creatinine, urate and LDH. Check infection and baseline organ function; cardiac assessment matters before anthracyclines. ALL evaluation includes CNS assessment by lumbar puncture when safe and appropriately timed, not before stabilization of bleeding or pressure risks.

AML treatment logic

For appropriate fit patients, the classic 7+3 induction pairs seven days of cytarabine with three days of an anthracycline. Consolidation eliminates residual disease; adverse-risk genetics and response may favour allogeneic hematopoietic stem-cell transplantation (HSCT). Fitness, age and disease genetics determine whether intensive or lower-intensity/targeted treatment is appropriate.

Transfusions, infection treatment/prevention and tumour-lysis monitoring are integral. Surgery is mainly diagnostic or complication-directed; systemic treatment is the mainstay. Radiation has selected uses, so the source statement that it is never an option is too absolute.

ALL and pediatric treatment

Childhood ALL is commonly treated over 2–3 years, with substantial outpatient therapy once stable. CNS-directed intrathecal treatment is routine; radiation is reserved for selected situations. Sanctuary sites explain why a clean blood count does not eliminate the need for CNS-directed therapy.

Intensive pediatric AML treatment commonly requires prolonged hospitalization. Treatment intensity reflects disease biology, protocol and tolerability, not simply that children are 'durable'. Pediatric ALL outcomes are generally much better than adult ALL; the review uses about 90% cure. The old note's pediatric AML survival figure of 40% is historical: NCI reports approximately 69–72% five-year survival in recent age-group data. NCI pediatric AML evidence.

Do not confuse the immune therapies

Blinatumomab brings CD19-positive B cells beside CD3-positive T cells: a bispecific T-cell engager. Inotuzumab ozogamicin is an anti-CD22 antibody carrying a cytotoxic payload. CAR-T treatment instead modifies the patient's T cells. These are distinct platforms, although all may have roles in selected B-ALL settings. NCI blinatumomab; NCI inotuzumab.

Review questions
A child has pallor, bleeding, bone pain and lymphadenopathy. What diagnosis must be considered?

Acute leukemia, particularly ALL; the symptoms reflect marrow failure and tissue infiltration.

Does a marrow blast count below 20% always exclude AML?

No. AML-defining genetic abnormalities can permit diagnosis below that threshold under modern classifications.

28

APL and leukemia emergencies

Four patterns demand immediate recognition: bleeding from APL/DIC, tumour lysis, leukostasis and fever with severe neutropenia.

APL: differentiation stops at the promyelocyte

Acute promyelocytic leukemia is a genetically defined AML with t(15;17), PML::RARA. Abnormal retinoic-acid signalling blocks maturation. Hypergranular promyelocytes with bundles of Auer rods strongly suggest it; flow often shows absent HLA-DR. A microgranular variant exists and may present with leukocytosis.

The course estimates APL at 10–15% of AML. Its distinctive threat is early catastrophic hemorrhage, including intracranial bleeding. Promyelocytes promote both coagulation activation and excessive fibrinolysis; platelets and clotting factors become depleted. A low presenting WBC does not make it safe.

Suspect APL → act before confirmation

Start ATRA immediately when APL is suspected while arranging urgent specialist management, rapid PML::RARA confirmation and aggressive support of the coagulopathy. Do not wait for the final genetic report. ATRA restores differentiation; arsenic trioxide is a key partner, with additional cytoreduction/chemotherapy in higher-risk disease. European LeukemiaNet APL recommendations.

DIC clues are bleeding/oozing, low platelets and fibrinogen, high D-dimer and prolonged PT/INR and often aPTT; schistocytes can appear. Blood-product support and treatment of the underlying APL address different parts of the emergency. During differentiation therapy, fever, respiratory distress, edema and hypotension can signal differentiation syndrome and require urgent assessment.

Tumour lysis: the K–phosphate–urate–calcium pattern

Rapid tumour breakdown, spontaneous or treatment-triggered, releases intracellular potassium and phosphate; nucleic acids become uric acid. Calcium falls as calcium phosphate precipitates. Remember ↑K, ↑phosphate, ↑urate, ↓Ca, rising creatinine.

Consequences include arrhythmia, seizures, acute kidney injury and death. Give monitored hydration, frequent laboratory checks and appropriate urate-lowering treatment; severe refractory electrolyte disturbance, fluid overload or renal complications may require dialysis.

Allopurinol prevents new uric acid formation; it does not remove urate already present. Rasburicase breaks down existing uric acid and is important in established/high-risk TLS; it is contraindicated in G6PD deficiency. eviQ TLS guidance.

Do not routinely replace asymptomatic low calcium: extra calcium may worsen calcium-phosphate deposition. Symptomatic hypocalcemia needs expert-directed treatment. The old review question treating every low calcium as automatically correctable is oversimplified. MD Anderson TLS algorithm.

Leukostasis: symptoms matter more than a magic count

Large, poorly deformable blasts and endothelial interactions obstruct the microcirculation. Think of dyspnea/hypoxia, headache, confusion, visual changes or focal neurologic findings in acute leukemia with a high blast burden. Other manifestations include cardiac ischemia, renal injury, priapism and limb/bowel ischemia.

Urgent specialist-directed cytoreduction and supportive care are central. Hydroxyurea and definitive leukemia therapy reduce cells; leukapheresis is considered in selected cases and is not automatic for every high WBC. It is generally avoided in APL because of bleeding concerns. Simultaneously anticipate tumour lysis.

One distinction per emergency

PatternThink first
APL with IV-site oozing and low fibrinogenDIC/hyperfibrinolysis; urgent ATRA and blood-product support.
After treatment: ↑K, ↑phosphate, ↑urate, ↓CaTumour lysis; metabolic/renal emergency.
High blast burden plus hypoxia or neurologic dysfunctionLeukostasis; urgent cytoreduction.
Fever with severe/anticipated severe neutropeniaFebrile neutropenia; empiric antibiotics urgently.
Review questions
Which leukemia treatment begins on suspicion rather than waiting for final genetics?

ATRA for suspected acute promyelocytic leukemia.

Why is rasburicase more useful than allopurinol for existing hyperuricemia?

Rasburicase degrades uric acid already present; allopurinol blocks formation of new uric acid.

29

Chronic leukemias: CML and CLL

CML is a granulocyte-producing clone driven by BCR::ABL1. CLL is a mature B-cell clone whose complications can be immune as well as infiltrative.

CML: mature cells, abnormal driver

Chronic myeloid leukemia preserves much of myeloid maturation. Blood may contain neutrophils and their precursors, especially myelocytes, plus basophilia, eosinophilia and sometimes thrombocytosis. Splenomegaly may cause fullness/early satiety. Fatigue, sweats, weight loss and anemia can occur, but diagnosis is often incidental.

t(9;22) creates the Philadelphia chromosome and BCR::ABL1 fusion tyrosine kinase. Confirm with appropriate molecular/cytogenetic testing. Marrow shows granulocytic proliferation; baseline marrow/cytogenetics and quantitative PCR characterize and monitor disease.

CML phases and treatment

The course's three-phase model is chronic (<10% blasts), accelerated and blast phase. Blast phase generally means ≥20% blasts or extramedullary blast proliferation. It can be myeloid or lymphoid; the slide's 'conversion to AML' is only one possibility.

Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib or nilotinib target BCR::ABL1. Monitor molecular response and resistance. Supportive urate prophylaxis may be needed initially. Allogeneic HSCT is potentially curative and used selectively, particularly for resistant/advanced disease.

CML, MDS and other MPNs can evolve to acute leukemia. DLBCL is a lymphoid lymphoma, so it is the intended contrast in the review question asking which listed disease has the lowest direct AML-transformation tendency.

CLL: a mature B-cell clone

Chronic lymphocytic leukemia usually affects older adults. Small mature-appearing clonal B cells accumulate in blood, marrow, lymph nodes and spleen. Smudge cells are fragile disrupted cells on a film; they are a clue rather than a stand-alone diagnostic test.

Typical flow pattern: CD19+, CD5+, CD23+, dim CD20, with light-chain restriction. Small lymphocytic lymphoma (SLL) is the tissue-predominant counterpart; monoclonal B-cell lymphocytosis (MBL) is a lower-burden precursor state. Molecular/FISH findings, TP53 status and IGHV mutation status help assess prognosis and guide therapy.

CLL staging and immune consequences

The course uses Rai 0 = low, I–II = intermediate, and III–IV = high-risk clinical stage. Lymphadenopathy and organ enlargement represent increasing distribution; anemia and thrombocytopenia signal advanced marrow/immune effects.

CLL can cause autoimmune hemolytic anemia and immune thrombocytopenia. Hypogammaglobulinemia and sometimes neutropenia increase infection risk. Thus many circulating lymphocytes do not equal effective immunity.

Watchful waiting has a purpose

Asymptomatic early CLL often needs surveillance rather than immediate treatment. Symptoms, progressive cytopenias, bulky/progressive disease and other established criteria trigger treatment. The course names anti-CD20 antibodies, ibrutinib and historical chemotherapy examples chlorambucil/fludarabine; contemporary regimen choice depends on genetics, comorbidity and local guidance.

Ibrutinib inhibits Bruton's tyrosine kinase (BTK); bruising/bleeding and atrial fibrillation are key adverse effects. CLL is generally controllable but not routinely curable with standard drug therapy. Old median-survival figures are cohort-dependent and should not be used as individual predictions.

Review questions
Is CML blast phase always AML?

No. It can be myeloid or lymphoid blast phase.

Why can a patient with a very high CLL lymphocyte count still have recurrent infections?

The malignant lymphocytes do not provide normal immune function; hypogammaglobulinemia and treatment/marrow effects further impair defence.

30

Erythrocytosis and polycythemia vera

An elevated hemoglobin may reflect reduced plasma volume, a response to erythropoietin, or autonomous marrow production.

First confirm what is high

Relative erythrocytosis is hemoconcentration from reduced plasma volume; absolute erythrocytosis is increased red-cell mass. Confirm persistence, hydration status and the laboratory reference range. The notes use Hb >170 g/L in men and >160 in women as a screening shorthand; PV diagnostic criteria use different thresholds.

Check oxygenation, smoking/carbon-monoxide exposure, sleep-apnea symptoms, cardiopulmonary disease, altitude, kidney disease and drugs such as testosterone/androgens or exogenous EPO. If WBCs and platelets are also elevated, panmyelosis makes PV more likely.

EPO organizes the differential

PatternMechanismExamples
Low EPOAutonomous/primary red-cell productionPV; rare congenital EPO-receptor mutations.
Normal/high EPO: systemic hypoxiaKidney detects inadequate oxygen deliveryCOPD, obstructive sleep apnea, right-to-left cardiac shunt, smoking and high altitude.
Normal/high EPO: renal stimulusLocal renal hypoxia or altered regulationRenal artery stenosis, renal cysts, post-transplant erythrocytosis.
Inappropriate EPO or drug effectHormone production/stimulation despite adequate oxygenRenal-cell or hepatocellular carcinoma, cerebellar hemangioblastoma, pheochromocytoma; EPO/androgens.
Congenital secondary causesAltered oxygen sensing/deliveryOxygen-sensing pathway defects or high-affinity hemoglobin.

EPO is a discriminator, not a perfect stand-alone rule. Direct investigations by the findings: sleep study, pulmonary function testing, echocardiography, renal/abdominal imaging or genetic workup.

Why JAK2 causes PV

Normal EPO-receptor signalling activates JAK2, then pathways such as STAT, PI3K and RAS/MAPK to support proliferation. Acquired somatic JAK2 V617F alters the regulatory pseudokinase domain; signalling stays active without the usual EPO stimulus.

Most PV carries V617F; some has JAK2 exon 12 mutations. The notes' 90–95% figure refers chiefly to V617F, not the total proportion with any JAK2 mutation. JAK2 lies on chromosome 9; V617F denotes valine-to-phenylalanine substitution at position 617.

Recognize and diagnose PV

Classic clues are itch after bathing (aquagenic pruritus), ruddy complexion, splenomegaly, early satiety, erythromelalgia (burning red extremities), headaches/ocular migraine, dizziness, paresthesia and gout. Major consequences include arterial/venous thrombosis, bleeding, myelofibrosis and AML transformation.

The course's PV criteria are: (1) Hb >165 g/L in men or >160 in women, Hct >49% or >48%, or increased red-cell mass; (2) age-adjusted hypercellular marrow with trilineage proliferation and mature pleomorphic megakaryocytes; (3) JAK2 V617F or exon 12 mutation. Low EPO is the minor criterion. The usual rule is all three major criteria, or the first two plus the minor criterion, with context-specific biopsy exceptions.

Treatment prevents thrombosis

The central targets are hematocrit <0.45 and low-dose aspirin (the course example is 81 mg daily) when appropriate. Low-risk PV is usually managed with phlebotomy; age around 60 or older and previous thrombosis identify higher-risk disease that commonly needs cytoreduction such as hydroxyurea. Manage smoking, hypertension, diabetes and lipids.

Phlebotomy mainly lowers the red-cell mass. Hydroxyurea suppresses marrow production across cell lines. Aspirin needs caution with bleeding or acquired von Willebrand dysfunction, particularly with extreme thrombocytosis. Secondary hypoxic erythrocytosis is usually treated by correcting its cause; routine PV-style phlebotomy is not assumed.

Review questions
What does low EPO suggest in persistent erythrocytosis?

Primary/autonomous production, especially PV; follow with JAK2 and appropriate marrow assessment.

How do phlebotomy and hydroxyurea differ?

Phlebotomy removes red-cell mass; hydroxyurea reduces marrow cell production more broadly.

31

Thrombocytosis, myelofibrosis and pancytopenia

Count abnormalities become easier when you ask whether they are real, reactive, clonal, or caused by loss of marrow function.

A high platelet count: real, reactive or clonal?

Thrombocytosis = platelets ≥450 × 109/L; ≥1,000 is extreme. Repeat the CBC and inspect the smear. Red-cell fragments, neoplastic fragments, cryoglobulin crystals or bacteria can rarely be miscounted as platelets.

Reactive causes are more common: bacterial infection, IBD/RA/SLE, trauma/surgery/burns, hemorrhage, iron deficiency, hemolysis, cancer, hyposplenism/splenectomy and recovery after myelosuppression. Use ferritin/iron studies, inflammatory markers or hemolysis testing when suggested. Treat the cause and repeat the count.

Persistent unexplained thrombocytosis raises ET, PV, prefibrotic/primary myelofibrosis, CML or an MDS/MPN overlap; familial thrombocytosis is uncommon. Review other lines: very high Hb suggests PV; neutrophilia/basophilia and BCR::ABL1 suggest CML.

Essential thrombocythemia

ET is a clonal megakaryocyte disorder. It can cause microvascular symptoms such as erythromelalgia and ocular migraine, thrombosis, or bleeding despite the high platelet count. Weakness/dizziness occur; marked splenomegaly is less typical than in myelofibrosis.

The course criteria combine platelets ≥450; marrow dominated by enlarged mature hyperlobulated megakaryocytes; exclusion of PV, CML, PMF, MDS and other myeloid neoplasms; and JAK2, CALR or MPL mutation. An alternative clonal marker or exclusion of reactive thrombocytosis serves as a minor criterion. Count alone cannot diagnose ET.

Management is individualized to thrombotic/bleeding risk; selected patients receive antiplatelet therapy and cytoreduction. Extreme counts may cause acquired von Willebrand dysfunction, so automatically giving aspirin can worsen bleeding.

Primary myelofibrosis

Clonal atypical megakaryocytes and marrow fibrosis disrupt normal production. Blood may show teardrop red cells and a leukoerythroblastic film—nucleated red cells plus immature myeloid forms. Extramedullary hematopoiesis contributes to a large spleen, early satiety and constitutional symptoms.

The course's overt PMF major criteria are atypical megakaryocytic proliferation with grade 2–3 reticulin/collagen fibrosis; a JAK2/CALR/MPL mutation, other clonal marker or exclusion of reactive fibrosis; and exclusion of another myeloid neoplasm. Supporting minor findings include unexplained anemia, WBC ≥11, palpable splenomegaly, elevated LDH and leukoerythroblastosis.

Symptoms and goals guide supportive transfusions, selected erythropoietin/steroids/cytoreduction and JAK inhibition such as ruxolitinib. Allogeneic HSCT is potentially curative for selected patients. Fibrosis can also follow PV or ET.

The MPN family and evolution

MPNs arise from clonal stem cells with excess production of one or more myeloid lineages. Common themes are splenomegaly, thrombosis/bleeding, constitutional symptoms and possible acute-leukemia transformation. CML is BCR::ABL1-positive; PV/ET/PMF are the key BCR::ABL1-negative MPNs.

The review's image gives broad historical transformation ranges: PV/ET to myelofibrosis around 10–20%, PV/ET to AML around 2–7%, and myelofibrosis to AML around 8–30%. No time horizon is supplied, so use these only to understand relative risk, not as annual rates or individual predictions. ET generally has a more indolent course than PMF.

Pancytopenia: all three lines down

Recognize the symptom triad: fatigue from anemia, bleeding from thrombocytopenia, infection from leukopenia. Sort the causes by mechanism:

Low productionDestruction/consumptionSequestration
Aplastic/congenital marrow failure; MDS, AML or CMML; myelofibrosis; lymphoma/metastatic marrow infiltration; vitamin deficiency.Immune disease, medication effects, infection or connective-tissue disorders; sometimes no clear cause initially.Hypersplenism with an enlarged spleen.

CBC trends, reticulocytes, film, nutritional/hemolysis tests and, when needed, marrow distinguish these. A low count in every line should not be attributed to a single-cell disorder without further assessment.

Review questions
What is the commonest broad category of thrombocytosis?

Reactive thrombocytosis, often from infection, inflammation, iron deficiency, blood loss or reduced splenic function.

Teardrops, nucleated RBCs, immature myeloid cells and splenomegaly suggest what?

Myelofibrosis or another marrow-infiltrating process producing a leukoerythroblastic picture.

Week 12

Lymphoma, myeloma & cancer treatment

Connect lymphoid biology, tissue diagnosis, systemic therapy, and radiation oncology.

32

Adaptive immunity and lymph-node anatomy

Lymph nodes are meeting places: antigen-presenting cells, T cells and B cells come together to build a specific immune response.

Where cells develop, and where they respond

Primary lymphoid organs are bone marrow for B-cell development and thymus for T-cell development. Secondary lymphoid organs include lymph nodes, spleen and mucosa-associated lymphoid tissue, including gut-associated lymphoid tissue (MALT/GALT).

Mature naive B and T cells leave their developmental sites and recirculate in search of antigen. Lymph nodes filter lymph from tissues; the spleen samples blood. Lymphoid tissue is particularly prominent in children and adolescents.

The node map

Lymph enters through afferent vessels and leaves through an efferent vessel at the hilum. B-cell follicles lie in the cortex; activated follicles develop germinal centres. The paracortex is the T-cell zone. Lymphocyte proliferation during immune responses explains why a reactive node enlarges.

This architecture matters diagnostically: lymphoma may replace normal compartments, create abnormal follicles or grow diffusely. A tissue sample that preserves the architecture is more informative than isolated cells alone.

Three signals activate a naive T cell

  1. Specificity: the T-cell receptor recognizes a peptide presented by an MHC molecule on an antigen-presenting cell (APC).
  2. Co-stimulation: CD28 on the T cell interacts with CD80/CD86 (B7) on the APC.
  3. Direction: cytokines shape proliferation and differentiation.

Dendritic cells detect pathogens through innate mechanisms, mature, migrate into the T-cell area and increase co-stimulatory molecules. This connects an early innate response to later adaptive immunity.

B cells improve their antibodies

Activated B cells can become antibody-secreting plasma cells. T-independent responses tend to produce lower-affinity IgM. T-dependent responses support germinal-centre reactions, high-affinity antibodies and memory.

In a germinal centre, B cells proliferate and undergo somatic hypermutation in immunoglobulin variable-region genes; selection favours cells with better antigen binding. The notes' teaching timeline is antigen arrival around day 0–1, early T-cell proliferation, early antibodies/germinal centres over the next few days, and higher-affinity antibodies around days 8–10. Exact timing varies with antigen and prior immunity.

Review questions
Where are T cells and B-cell follicles located in a node?

T cells mainly occupy the paracortex; B-cell follicles occupy the cortex.

What are the three signals for naive T-cell activation?

Peptide–MHC recognition by the TCR, co-stimulation through CD28–CD80/86, and cytokine signals.

33

Approach to lymphadenopathy

Most enlarged nodes are reactive. Location, persistence, examination and systemic features determine which need targeted investigation or biopsy.

Confirm that the lump is a node

Lymphadenopathy means abnormal nodal size or character. A lipoma, cyst, hematoma, hemangioma or fibroma can mimic a node. Describe isolated versus regional disease and whether multiple noncontiguous regions are involved.

The source estimates that >98% of enlarged nodes in primary care are nonmalignant, particularly in younger people. That is a setting-specific reassurance, not permission to ignore red flags. Small cervical or inguinal nodes may be palpable in healthy people; the note's 'only inguinal nodes are normally palpable' is overly absolute.

Drainage is a diagnostic clue

Node groupLook in the drainage areaImportant possibilities
Preauricular/posterior cervicalScalp, head/neck skinSkin infection, mycobacteria; skin/head-and-neck cancer, lymphoma.
Submandibular/anterior cervicalTeeth, mouth, tongue, pharynx/larynxDental disease, viral/bacterial URTI, EBV/CMV, toxoplasma; head-and-neck squamous carcinoma, leukemia/lymphoma.
SupraclavicularThorax and abdomenIntrathoracic/intra-abdominal malignancy; mycobacterial/fungal infection. This location is a red flag.
InfraclavicularRegional thoracic drainageLymphoma and other regional disease.
AxillaryBreast, arm, chest wallSkin infection/trauma, cat-scratch disease; breast carcinoma, melanoma, lymphoma/leukemia, soft-tissue/Kaposi sarcoma.
EpitrochlearUlnar forearm and handLocal infection, secondary syphilis; lymphoma or skin malignancy.
InguinalLeg, lower abdominal wall, external genital skin, anal region and lower vaginaSkin infection, STI; penile/vulvar/anal carcinoma, lymphoma, skin/soft-tissue malignancy.

History and examination in useful chunks

  • Time: onset, growth, fluctuation, duration and previous episodes.
  • Systemic: fever, drenching night sweats, unintended weight loss, fatigue and pruritus.
  • Exposures: infections in the drainage territory, cat scratches/ticks, travel, sexual exposure, medications and smoking.
  • Inflammatory clues: rash, mouth ulcers, arthritis, myalgia or other autoimmune features.
  • Character: size, tenderness, firmness, mobility, matting and skin changes. Examine other node regions, tonsils, liver and spleen and the relevant drainage territory.

Check stability first. A mediastinal mass causing respiratory distress is a different level of urgency from a small improving cervical node after a cold.

The full differential, grouped

  • Infection: staph/strep, TB/other mycobacteria, syphilis, Bartonella, Lyme disease; EBV, CMV, HIV/hepatitis; toxoplasmosis; histoplasma/cryptococcus. Axillary exposure histories can suggest tularemia, sporotrichosis, brucellosis or leishmaniasis.
  • Inflammatory/immune: sarcoidosis, SLE, RA, dermatomyositis, scleroderma, Kikuchi disease, Kawasaki disease or autoimmune lymphoproliferative syndrome.
  • Drug/serum-sickness reactions: antiepileptics such as phenytoin/carbamazepine/phenobarbital, sulfonamides and other antibiotics, allopurinol, hydralazine, atenolol and other implicated drugs.
  • Malignancy/lymphoproliferation: lymphoma, leukemia, metastatic solid tumour, post-transplant lymphoproliferative disease or Castleman disease.
  • Other systemic disease: selected endocrine/metabolic disease, lipid-storage disorders, amyloidosis or hemophagocytic lymphohistiocytosis.

The notes use VITAMIN C as a broad category prompt: vascular, infectious, trauma, autoimmune, metabolic, iatrogenic, neoplastic and congenital.

The source medication list also names aspirin, isoniazid, iodine preparations, tetracyclines, penicillins, cephalosporins, phenylbutazone and other barbiturates. A medication association is a differential clue, not proof that a drug caused an individual node.

Red flags and sensible next steps

Concerning features include a supraclavicular location; fixed, matted, non-tender or enlarging nodes; a large node around ≥2 cm; generalized disease; B symptoms; unexplained cytopenias/blasts; mediastinal/hilar abnormalities; or persistent inflammatory markers. Absence of ENT infection removes one reassuring explanation but does not prove cancer.

Low-risk localized nodes may be observed with a defined follow-up, often about a month. Treat a demonstrated bacterial cause; empiric antibiotics are not a mandatory step for every unexplained node. Generalized or persistent unexplained nodes warrant targeted tests and sometimes biopsy.

Tests can include CBC/film, LDH, renal/liver function, calcium/albumin, HIV/hepatitis and exposure-directed serology/cultures; ultrasound, chest imaging or CT according to location and age. Ultrasound avoids radiation and is often useful in children; the source's 'over 14' imaging wording is a noted probable typo. Send biopsy material for histology/flow and infection studies when indicated.

Review questions
Why is a supraclavicular node especially concerning?

It can reflect intrathoracic or intra-abdominal disease, including malignancy, so it deserves careful evaluation.

Does a tender node prove infection and exclude cancer?

No. Tenderness is one clue; persistence, location, growth, systemic symptoms and the overall evaluation matter.

34

Lymphoma: diagnosis, staging and prognosis

Establish the tissue diagnosis first. Subtype, distribution, tumour burden and patient fitness then guide treatment.

What lymphoma means

Lymphoma is a malignant lymphoid proliferation presenting in nodes, lymphoid organs or extranodal tissues. Hodgkin lymphoma (HL) usually has rare malignant cells within a rich reactive background. Non-Hodgkin lymphoma (NHL) includes many B-, T- and NK-cell diseases with widely different behaviour.

Classify NHL by lineage, mature versus precursor state, cell size, architecture (follicular/diffuse), anatomic origin, genetics, distribution and clinical aggressiveness. Roughly 85–90% in the course framework are B-cell; T/NK diseases make up the remainder. Modern classifications are more detailed than the source's WHO-2016 shorthand.

Why biopsy type matters

MethodWhat it givesLimitation
Fine-needle aspiration (FNA)Quick, minimally invasive cells; useful for selected questions such as metastatic carcinoma.Little/no architecture; may miss focal disease, transformation or low-grade lymphoma; often inadequate for initial lymphoma classification.
Core biopsyTissue cylinders with some architecture; image guidance reaches deep lesions; fresh material can go to flow.Limited sampling; sometimes insufficient for all studies or heterogeneous disease.
Excisional biopsyWhole node/large sample, architecture and ample material for ancillary tests.More invasive; site/access and patient condition matter. Still not immune to sampling or interpretation error.

Excision is preferred when feasible for suspected lymphoma; a core is reasonable when surgery is less suitable. Neither a universal >1-cm biopsy rule nor 'excision has no false negatives' is correct. Choose the most informative suspicious accessible tissue. NICE lymphoma biopsy guidance.

Ancillary tests complete the diagnosis

Immunohistochemistry shows markers in tissue context; flow cytometry characterizes cells in suspension; FISH/molecular testing identifies defining or prognostic genetic changes. B-cell markers include CD19/CD20/CD79a; T-cell markers CD3/CD5/CD7. Light-chain restriction can support a B-cell clone.

Baseline assessment includes CBC, chemistry, LDH, viral screening and appropriate imaging, usually CT/PET-CT for relevant subtypes. PET measures metabolic activity rather than proving lymphoma by itself. Marrow biopsy, lumbar puncture and cardiac assessment are ordered when the subtype, stage or planned therapy warrants them.

Ann Arbor/Lugano anatomy

StageDistribution
IOne nodal region; IE denotes a single localized extranodal site.
IITwo or more nodal regions on the same side of the diaphragm; limited contiguous extranodal extension may be described with E.
IIINodal disease above and below the diaphragm, including relevant splenic involvement.
IVDisseminated extranodal involvement, for example marrow or diffuse liver disease.

B symptoms are unexplained fever >38°C, drenching night sweats, or >10% unintended weight loss in six months. A means absent, B present in the course's Ann Arbor notation; A/B remains especially relevant to HL. One cervical region plus drenching sweats is IB, even if the node itself is large.

Prognostic scores: what the mnemonics mean

  • DLBCL IPI — APLES: age >60, poor ECOG performance (functional status), elevated LDH, >1 extranodal site and stage III/IV.
  • Follicular FLIPI — No LASH: >4 nodal areas, elevated LDH, age >60, stage III/IV and Hb <120 g/L.
  • Early HL — No LEE: multiple nodal regions (review uses >2), large mediastinal mass, elevated ESR and extranodal disease. Exact unfavourable-risk cutoffs differ between cooperative groups.
  • Advanced HL IPS: albumin <40 g/L, Hb <105 g/L, male sex, age ≥45, stage IV, WBC ≥15 × 109/L and lymphocytes <0.6 × 109/L or <8% of WBC. ACR advanced Hodgkin review.

Stage describes distribution; a prognostic score combines disease and patient features. Neither replaces subtype or response to treatment.

Review questions
Why is FNA often insufficient for a new lymphoma diagnosis?

It loses nodal architecture and may provide too few cells for complete subtype/genetic assessment.

Nodes above and below the diaphragm, with no disseminated extranodal disease, are which stage?

Stage III.

35

Hodgkin lymphoma

Think of malignant B-lineage cells hiding within a large reactive background. Pattern, markers and stage distinguish the major forms.

Clinical pattern

HL often presents in a young adult with painless cervical or supraclavicular lymphadenopathy and relatively orderly contiguous spread between nodal regions. Mediastinal involvement is common in nodular sclerosis. B symptoms, pruritus and occasionally pain in nodes after alcohol are useful clues.

Classical HL arises from germinal-centre B cells. Large Reed–Sternberg (RS) cells or variants sit among reactive lymphocytes, eosinophils and other inflammatory cells. The background may appear polyclonal on routine flow, so a nondiagnostic flow result does not exclude HL.

Classical subtypes

SubtypeKey pathology/presentationCourse emphasis
Nodular sclerosisBroad collagen bands and lacunar RS variants; often young adults and a mediastinal mass.Most common, roughly 70%; often early-stage with excellent outcomes.
Mixed cellularityRS cells in a mixed inflammatory background without nodular sclerosis; stronger EBV association and more frequent with HIV.About 20% of classical HL in the notes; often advanced/B symptoms.
Lymphocyte-richMany benign lymphocytes and relatively few RS cells.Uncommon; generally favourable.
Lymphocyte-depletedRelatively numerous atypical RS cells and few background lymphocytes.Rare, often advanced; adverse presentation in the course comparison.

Typical classical RS-cell staining is CD30-positive, usually CD15-positive, usually CD45-negative; CD20 is variable, often weak/absent. The source's mixed-cellularity row should not be read as a rule that classical HL becomes CD45-positive.

Nodular lymphocyte-predominant disease

The course calls this NLPHL; newer classifications may call it nodular lymphocyte-predominant B-cell lymphoma. Its malignant lymphocyte-predominant cells have multilobed 'popcorn' nuclei and retain B-cell markers: CD20/CD45 positive, usually CD15/CD30 negative.

It usually affects peripheral nodes, is less often mediastinal or EBV-associated, and tends to be indolent with frequent late relapse. Transformation to an aggressive large B-cell lymphoma can occur. Its management differs from classical HL, so do not apply every classical-HL statement automatically.

Treatment: learn the course regimen and its limits

The review emphasizes ABVD: Adriamycin/doxorubicin, bleomycin, vinblastine and dacarbazine. Early favourable classical HL often receives a short systemic course with involved-site radiation. Advanced disease needs full systemic treatment; PET response can guide dropping bleomycin or additional local therapy.

The website example 'ABVD ×2, then AVD ×4' describes a response-adapted approach, not a universal prescription. Current options also include nivolumab-AVD or brentuximab-AVD in appropriate settings. The educational goal is curative treatment matched to stage, risk and response. NCI Hodgkin treatment evidence.

Monitor treatment toxicities as well as relapse: bleomycin lung injury, anthracycline cardiac injury, infertility and later radiation/therapy-associated cancers are relevant long-term considerations.

Review questions
Young adult, mediastinal mass, collagen bands and lacunar cells: which classical HL subtype?

Nodular sclerosis.

How do popcorn cells differ immunophenotypically from typical classical RS cells?

Popcorn/LP cells are usually CD20+/CD45+ and CD15−/CD30−; classical RS cells are usually CD30+, often CD15+, and CD45−.

36

Non-Hodgkin lymphoma and signature genetics

The most useful first distinction is aggressive disease that needs prompt treatment versus indolent disease that may be observed while asymptomatic.

Aggressive does not mean incurable

Diffuse large B-cell lymphoma (DLBCL) often causes a rapidly enlarging painless mass, with or without B symptoms and extranodal involvement. It is the most common NHL subtype. Histology shows diffuse sheets of large malignant B cells with prominent nuclei/nucleoli and high proliferation.

Untreated disease can progress quickly, but treatment often has curative intent. The source's phrase 'some T-cell' is incorrect for DLBCL itself: large T-cell lymphomas are distinct diagnoses. Germinal-centre B-cell-like (GCB) and activated B-cell-like (ABC) biology can affect prognosis; CD10 expression is variable, not universal.

R-CHOP: decode the name

LetterDrugWhat to remember
RRituximabAnti-CD20 B-cell antibody.
CCyclophosphamideDNA-crosslinking cytotoxic.
HHydroxydaunorubicin = doxorubicinAnthracycline; heart toxicity.
OOncovin = vincristineMicrotubule inhibitor; neuropathy.
PPrednisoneGlucocorticoid with lymphoid cytotoxic effects.

The course example is a 21-day cycle, with IV drugs around day 1 and prednisone on days 1–5. Limited-stage versus advanced-stage treatment duration and use of radiation depend on risk, bulk and response; the slide's 3-versus-6-cycle summary is not universal. R-CHOP is the classic examination association, while modern care includes other regimens in selected patients.

Follicular lymphoma: slow, relapsing, sometimes observed

Follicular lymphoma usually affects older adults with slowly enlarging or waxing-and-waning nodes, often widespread at diagnosis. Tumour cells form abnormal follicles and commonly carry t(14;18), IGH::BCL2. BCL2 promotes survival by resisting apoptosis.

Asymptomatic low-burden advanced disease may be monitored. Treatment is indicated when disease burden, symptoms or organ effects warrant it; the notes use bendamustine–rituximab followed by maintenance rituximab as an example. Localized stage I disease may be treated with radiation with curative potential.

Remission is possible even when advanced disease is not usually cured. Thus the review's indolent-versus-aggressive question should not equate 'incurable' with 'never achieves complete remission'. A sudden rapidly growing site or new systemic symptoms can indicate transformation, often to DLBCL.

Genetics worth recognizing

ChangeGene/pathwayAssociation
t(8;14)MYC linked to immunoglobulin regulationBurkitt lymphoma; very high proliferation and a starry-sky pattern from macrophages clearing dying cells.
t(14;18)BCL2Follicular lymphoma.
t(11;14)CCND1/cyclin D1Mantle-cell lymphoma.
t(11;18)BIRC3::MALT1Some MALT/marginal-zone lymphomas.
t(2;5)NPM1::ALKA subset of ALK-positive anaplastic large-cell lymphoma.

These are characteristic associations, not substitutes for a complete diagnosis. FISH for MYC/BCL2/BCL6 can refine aggressive B-cell classification.

Other named categories and treatment principles

The roster includes small lymphocytic lymphoma/CLL, marginal-zone, lymphoplasmacytic, mantle-cell and Burkitt lymphomas among B-cell diseases; peripheral T-cell lymphoma, anaplastic large-cell lymphoma and mycosis fungoides among T-cell diseases; and NK-cell entities.

Systemic drugs treat dispersed disease; antibodies require the relevant target; radiation treats a defined field. Surgery is primarily used to obtain tissue, with occasional roles in complications. Watchful waiting is an active surveillance strategy for selected indolent disease, not a general lymphoma rule. SLL/CLL biology and immune complications are covered in chronic leukemias.

Review questions
Which lymphoma is aggressive yet often treated with curative intent using an R-CHOP-based approach?

Diffuse large B-cell lymphoma.

What does t(14;18) suggest, and what does its protein do?

Follicular lymphoma; BCL2 inhibits apoptosis and prolongs cell survival.

37

Monoclonal proteins and multiple myeloma

A plasma-cell clone can produce a detectable protein long before it causes organ damage. Diagnosis combines the clone, its protein and myeloma-defining events.

Normal antibody, abnormal clone

Plasma cells are terminally differentiated antibody-producing B cells, supported by the marrow environment. Each clone makes a particular immunoglobulin heavy chain (IgG, IgA, IgM, IgD or IgE) and light chain (kappa or lambda). Mature plasma cells usually lose CD20 and express plasma-cell markers such as CD38.

Myeloma is a malignant plasma-cell proliferation. Its monoclonal immunoglobulin or light chain is the M protein; normal effective antibody production may be suppressed. Myeloma predominantly affects older adults—the course median is about 66—and is more common in men. The notes' annual Canadian case counts are historical, not current epidemiology.

MGUS, smoldering disease and active myeloma

StateCore distinctionGeneral approach
Non-IgM MGUSSerum M protein <30 g/L, marrow clonal plasma cells <10%, no attributable myeloma-defining organ injury.Risk-adapted monitoring; many never progress.
Smoldering myelomaHigher M protein and/or marrow clonal plasma cells 10% to <60%, without a myeloma-defining event or amyloidosis.Risk-stratified surveillance; high-risk cases require a treatment discussion.
Active myelomaClonal marrow plasma cells ≥10% or a biopsy-proven plasmacytoma, plus an attributable CRAB feature or a SLiM biomarker.Anti-myeloma therapy and complication management.

The slide's 'no CRAB = always observe' rule is incomplete because SLiM biomarkers can define active myeloma before symptoms. Current high-risk smoldering management may include monitoring or daratumumab after specialist discussion; low-risk smoldering disease is generally observed. ASCO living myeloma guideline.

The source gives variable progression estimates: roughly 0.5–2% per year for MGUS and 5–25% for smoldering disease, with another table using 1% and 10–20%. Risk depends strongly on subtype, markers and time since diagnosis; these ranges are not interchangeable individual predictions.

CRAB: organ injury caused by the clone

LetterDiagnostic featureMechanism/clues
CCalcium >2.75 mmol/L or >0.25 mmol/L above the upper limit.Bone resorption; thirst, polyuria, nausea, constipation, confusion.
RCreatinine clearance <40 mL/min or creatinine >177 µmol/L.Light-chain injury, hypercalcemia and other contributors.
AHb <100 g/L or >20 g/L below the lower limit of normal.Marrow effects, kidney disease and other factors; fatigue/pallor.
BOne or more qualifying osteolytic lesions on appropriate imaging.Bone pain, fractures, often vertebral involvement.

These abnormalities must be attributable to the plasma-cell disorder. The note's calcium >2.52 and '20 below baseline' wording are not the formal IMWG thresholds. Osteoporosis or a compression fracture alone does not establish a qualifying lytic lesion. IMWG diagnostic criteria.

If clonal marrow plasma cells are below 10%, more than one bony lesion is required to distinguish myeloma from a solitary plasmacytoma with minimal marrow involvement.

SLiM: biomarkers that also define active disease

  • S: at least sixty percent clonal marrow plasma cells.
  • Li: involved-to-uninvolved free light-chain ratio ≥100, with involved free light chain ≥100 mg/L.
  • M: more than one MRI focal lesion, each at least 5 mm.

These sit alongside CRAB, not after it. BSH/UK Myeloma Forum criteria.

Find the clone, protein and injury

Order CBC/film, creatinine, calcium/albumin, total protein/immunoglobulins, LDH and appropriate marrow studies. Rouleaux means stacked red cells, favoured by increased plasma proteins.

Serum protein electrophoresis (SPEP) identifies an M spike; immunofixation identifies the heavy/light-chain type. Urine electrophoresis/immunofixation and serum free light chains detect light-chain disease. A missing M spike does not exclude light-chain or nonsecretory myeloma; SPEP alone does not diagnose myeloma.

Marrow morphology/flow establishes clonality and burden; FISH evaluates risk lesions such as t(4;14), t(14;16) and del(17p). Modern whole-body low-dose CT, PET-CT or MRI is more sensitive than a plain skeletal survey, although the older notes call the survey standard. Imaging choice follows the clinical question and availability.

Related plasma-cell disorders

  • Solitary plasmacytoma: a localized plasma-cell tumour, assessed carefully for systemic disease and often treated locally. Multiple lesions do not automatically mean 'end-stage', despite the slide's wording.
  • AL amyloidosis: misfolded light-chain material deposits in organs, notably heart and kidneys. It can coexist with a plasma-cell clone without overt myeloma.
  • POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes; a distinct plasma-cell-associated syndrome.
  • Plasma-cell leukemia: circulating malignant plasma cells with aggressive disease. The review's 20% threshold is historical; IMWG defines primary PCL with ≥5% circulating plasma cells on the blood smear in otherwise symptomatic myeloma. IMWG PCL consensus.

ISS and revised ISS are different

ISS I: beta-2 microglobulin <3.5 mg/L and albumin ≥35 g/L. ISS III: beta-2 microglobulin ≥5.5 mg/L. ISS II: neither I nor III.

R-ISS I adds standard-risk cytogenetics and normal LDH to ISS I. R-ISS III requires ISS III plus high-risk cytogenetics or elevated LDH. R-ISS II is the remainder. The slides mix ISS and R-ISS criteria; isolated high LDH does not automatically mean R-ISS III. Their 60/40/20-month survival figures are historical cohort summaries. Original IMWG R-ISS report.

Treat the myeloma and its consequences

Anti-myeloma regimens combine drug classes such as a proteasome inhibitor, immunomodulatory drug, glucocorticoid and/or monoclonal antibody, with autologous transplant in suitable patients. The review does not prescribe a complete modern regimen; know the drug–target associations in pharmacology.

ProblemPrinciple
New weakness/sensory change, sphincter symptoms or severe back painSuspect cord compression: urgent imaging and specialist treatment; steroids, radiation and/or surgery depend on the situation.
Acute kidney injuryPrompt anti-myeloma treatment and correction of reversible contributors; dialysis when indicated.
Hypercalcemia/bone diseaseHydration and appropriate antiresorptive treatment such as a bisphosphonate or denosumab; renal status matters.
Fracture/painAnalgesia, radiotherapy, orthopedic stabilization or selected vertebroplasty/kyphoplasty.
Anemia/thrombocytopeniaTreat disease; transfusions and selected erythropoietin according to indication.
Infection/cytopeniaVaccination/prevention, antibiotics, selected G-CSF or immunoglobulin replacement; therapy itself may suppress marrow.
Review questions
Can active myeloma be diagnosed before CRAB damage occurs?

Yes. A qualifying plasma-cell clone plus a SLiM biomarker can define active myeloma.

Why is a normal-looking SPEP not enough to exclude myeloma?

Light-chain or nonsecretory disease may not produce a conventional M spike; free light chains, immunofixation and marrow/imaging are important.

38

Anatomy and approach to a mediastinal mass

Localize the mass, identify threatened structures, and use a few focused markers to narrow the differential before choosing a biopsy.

The boundaries and compartments

The mediastinum lies between the lungs, bounded by the thoracic inlet above, diaphragm below, sternum anteriorly, vertebral column posteriorly and pleural spaces laterally. Traditional anatomical and modern imaging compartments are not identical; recognize which convention a question uses.

Course compartmentKey contentsMain differential
Anterior/prevascularThymus, fat/connective tissue, nodes and internal thoracic vessels.Ts: thymoma, thyroid, teratoma/germ-cell tumour, terrible lymphoma; consider a thoracic aortic/vascular lesion. Rarer fat, vascular, fibrous or parathyroid masses.
Middle/visceral regionHeart/pericardium, great-vessel structures, central airways and regional nodes; phrenic/recurrent laryngeal relationships matter.Lymphadenopathy from lymphoma, sarcoid or metastatic cancer; bronchogenic/pericardial/enteric cysts; esophageal or vascular lesions.
Posterior/paravertebral regionVertebrae, sympathetic chain and nerve structures; traditional posterior mediastinum also includes descending aorta, thoracic duct, esophagus, vagus and azygos system.Neurogenic tumours, meningoceles and thoracic spine lesions.

Tempo and mass effect

Very rapid progression over days can suggest lymphoblastic lymphoma or a nonseminomatous germ-cell tumour; progression over months fits many lymphomas/seminoma; years of slow growth may fit thymoma or mature teratoma. These are clues, not diagnostic timing rules.

  • Airway: cough, stridor, dyspnea or hemoptysis.
  • Esophagus: dysphagia.
  • Recurrent laryngeal nerve: hoarseness.
  • Heart/great vessels: chest symptoms, syncope, hypotension or tamponade physiology.
  • Systemic: B symptoms; myasthenia gravis suggests a thymic association.

Assess airway/breathing/circulation, vital signs, bilateral blood pressure when aortic disease is possible, and signs of cardiac compression. Look for nodes, thyroid/neck findings, splenomegaly and a testicular mass.

Two syndromes to recognize

Superior vena cava syndrome causes facial/neck/upper-chest swelling, venous collaterals, dyspnea and sometimes dysphagia/headache. Pemberton's manoeuvre can provoke facial congestion by raising the arms when thoracic-inlet venous flow is obstructed. Respiratory or neurologic compromise is urgent.

Horner syndrome reflects interruption of sympathetic supply: ipsilateral miosis, ptosis and anhidrosis. Apparent enophthalmos may accompany it. A posterior/apical thoracic lesion is one possible cause.

Imaging and marker shortcuts

A widened mediastinum on chest radiograph can reflect a mass, aneurysm, dissection or technical factors. The course quotes approximate >6 cm upright PA and >8 cm supine AP cutoffs, but projection and body habitus make width alone unreliable.

Contrast CT chest defines anatomy and relationships; MRI can clarify tissue planes/invasion; PET-CT is useful for selected lymphoma questions. Testicular ultrasound helps evaluate a germ-cell origin; radionuclide thyroid scanning can identify ectopic/substernal thyroid tissue when appropriate.

MarkerAssociation
Anti-acetylcholine receptor antibodiesMyasthenia gravis, sometimes associated with thymoma.
AFPNonseminomatous germ-cell components; pure seminoma should not elevate AFP.
Beta-hCGSome seminomatous and nonseminomatous germ-cell tumours.
LDHCell turnover/tumour burden, including lymphoma and germ-cell disease; nonspecific.

The lecture quotes AFP elevation in roughly 60–80% of nonseminomatous germ-cell tumours, and beta-hCG elevation in about 10% of seminomas and 30–50% of nonseminomatous tumours. Normal markers do not exclude a germ-cell tumour.

Plan tissue sampling around the diagnosis

Image-guided percutaneous core biopsy, endobronchial ultrasound sampling, mediastinoscopy, anterior mediastinotomy or video-assisted thoracoscopy are possible routes. Lymphoma needs adequate tissue and often fresh material for flow.

Do not biopsy a suspected aneurysm. A simple cyst may not need tissue. When imaging strongly suggests a resectable thymoma, upfront resection without pretreatment biopsy may be appropriate; unresectable or uncertain cases may need biopsy. 'Never biopsy thymoma' is too broad. ESMO thymic-tumour guidance.

Review questions
What are the classic anterior mediastinal Ts?

Thymic tumour, thyroid, teratoma/germ-cell tumour and terrible lymphoma; vascular/aortic lesions are also considered.

Facial swelling, dilated chest veins and dyspnea suggest which mass complication?

Superior vena cava obstruction/syndrome.

39

Pharmacology of hematologic malignancies

Learn each class as mechanism → representative drug → important use or toxicity. This makes the regimens easier to reconstruct.

Systemic versus local treatment

Systemic therapy reaches disseminated blood/marrow disease. Radiation treats an anatomical field. Surgery usually supplies diagnostic tissue, but can also treat selected localized lesions or complications. Cytotoxic combinations attack different vulnerabilities and limit resistance, while supportive care helps patients tolerate treatment.

Classic cytotoxic drugs often affect normal rapidly dividing tissues: marrow suppression, mucositis and alopecia are recurring patterns. The degree differs substantially by drug; the source's claim that every agent causes all three equally is too broad.

Classic cytotoxic classes

ClassMechanismExamples and key associations
Alkylating agentsCovalent DNA damage/crosslinks interfere with replication and trigger cell death.Cyclophosphamide, chlorambucil; cyclophosphamide in R-CHOP. Dacarbazine in ABVD.
Platinum compoundsDNA crosslinking; alkylating-like, chemically distinct from classic alkylators.Cisplatin, carboplatin.
AntimetabolitesInterfere with nucleotide production/use, especially during DNA synthesis.Methotrexate, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine; cytarabine in AML.
AnthracyclinesDNA intercalation, topoisomerase-II interference and reactive oxygen species.Doxorubicin/Adriamycin, daunorubicin.
Other antitumour antibioticBleomycin promotes DNA damage through free radicals.Bleomycin in ABVD; it should not simply be labelled a topoisomerase inhibitor.
Topoisomerase-II inhibitorsPrevent proper repair/handling of DNA strand breaks.Etoposide; anthracyclines also act here.
Vinca alkaloidsPrevent microtubule assembly and mitosis.Vincristine/Oncovin in R-CHOP; vinblastine in ABVD.
TaxanesStabilize microtubules so they cannot reorganize normally.Paclitaxel, docetaxel; mitotic arrest.

Organ-toxicity pairs

  • Cisplatin → kidney and ear injury. Carboplatin also has toxicity but is not identical in its renal/ototoxic profile.
  • Vincristine → peripheral/autonomic neuropathy.
  • Bleomycin → lung injury/fibrosis; busulfan is another pulmonary-toxicity association in the notes.
  • Doxorubicin → cardiomyopathy. Trastuzumab is another cardiac-toxicity example from the source diagram.
  • Cyclophosphamide → hemorrhagic cystitis.
  • Antimetabolites → marrow/mucosal toxicity, with additional drug-specific effects.

Pre-treatment organ assessment and monitoring reflect these toxicities: a baseline cardiac test before an anthracycline is a mechanistic precaution.

Antibodies, conjugates and engineered cells

PlatformExample/targetCore distinction
Unconjugated antibodyRituximab/obinutuzumab: CD20; daratumumab: CD38.Recruit immune killing/phagocytosis or other target-specific effects. Rituximab: B-cell lymphomas/CLL and selected autoimmune cytopenias; daratumumab: plasma-cell disease.
Antibody–drug conjugateBrentuximab vedotin: CD30; inotuzumab ozogamicin: CD22.Antibody delivers a cytotoxic payload. Brentuximab is not a naked antibody.
RadioimmunoconjugateIbritumomab tiuxetan; historical tositumomab example.Antibody delivers a radionuclide to targeted tissue; availability/use vary.
Bispecific T-cell engagerBlinatumomab: CD19 and CD3.Brings the tumour and a T cell together.
CAR-T cellsTisagenlecleucel, axicabtagene ciloleucel.Patient T cells engineered to recognize a target; selected B-ALL and lymphoma indications.

NCI brentuximab mechanism. Rituximab is the R in R-CHOP; it targets B cells rather than a generic marker on every lymphoma.

Small molecules: match the target

  • BCR::ABL1 TKIs: imatinib, nilotinib, dasatinib, bosutinib and ponatinib in appropriate CML settings. Imatinib also treats selected GIST. Edema, cramps, diarrhea and cytopenias are familiar; effusions and vascular risks differ by individual TKI.
  • BTK inhibitor: ibrutinib in B-cell disease such as CLL; remember atrial fibrillation and bruising/bleeding.
  • PI3K inhibitor: idelalisib is a pathway inhibitor, not a conventional receptor tyrosine-kinase inhibitor.
  • FLT3 inhibitors: selected genetically defined AML. The source's sunitinib example should not be used as the standard AML treatment association.
  • JAK inhibitor: ruxolitinib for selected MPN manifestations.
  • Proteasome inhibitor: bortezomib in myeloma.
  • Immunomodulatory drug: lenalidomide in myeloma and selected del(5q) MDS.
  • Differentiating therapy: ATRA for APL.

Checkpoint inhibitors and glucocorticoids

Pembrolizumab and nivolumab block PD-1, releasing an inhibitory immune signal; other drugs target PD-L1. Relevant uses include classical HL and selected solid tumours. Immune adverse effects include colitis, pneumonitis, hepatitis, rash, hypophysitis and nephritis; significant reactions often require treatment interruption and glucocorticoids.

The source SVG lists checkpoint inhibition for myeloma; do not learn that as routine myeloma treatment. Pembrolizumab combinations with immunomodulatory drugs/dexamethasone produced excess mortality. FDA safety action.

Prednisone/prednisolone and dexamethasone regulate gene expression through glucocorticoid receptors, reduce inflammatory signalling (including phospholipase-A2/arachidonic-acid and COX-2 pathways) and can kill lymphoid cells. They are used in lymphomas, leukemias, myeloma, autoimmune disease and tumour-associated edema. Anti-hormonal therapy for breast cancer is a broader oncology comparison in the notes, rather than a principal blood-cancer class.

Review questions
Which drug–toxicity pair distinguishes vincristine from doxorubicin?

Vincristine causes neuropathy; doxorubicin is associated with cardiac toxicity.

Is brentuximab vedotin a naked antibody or an antibody–drug conjugate?

An anti-CD30 antibody–drug conjugate carrying a cytotoxic payload.

40

Radiation oncology

Radiation damages DNA within a treatment field. Fraction size, total dose, tissue volume and timing determine the balance between tumour control and normal-tissue injury.

What radiation does

Ionizing radiation causes DNA damage directly and through reactive species. A cell may lose the ability to reproduce even without dying immediately. Normal tissue is also exposed, so planning aims for a favourable therapeutic ratio.

The spinal cord, bowel, kidneys and lungs are important organs at risk. There is no single universal tolerance dose: fraction size, total dose, exposed volume, prior treatment and organ biology all matter.

Delivery methods

MethodHow it is deliveredWhat to remember
External-beam radiation (EBRT)External photon or electron beams; most common overall method.Painless delivery; courses vary, often weekday treatments. The source gives 10–15-minute visits across 1–10 weeks as a typical teaching example.
BrachytherapyRadioactive source placed in/near the tumour.Low-dose-rate implants can deliver over days/months; high-dose-rate temporary sources deliver over minutes. Prostate and gynecologic applications.
IMRTIntensity-modulated beams shape dose around organs.Reduces high-dose exposure to uninvolved tissues.
SABR/SRSHighly focused stereotactic treatment, often in one to a few fractions.Large dose per fraction; precise immobilization/imaging. Gamma Knife, CyberKnife and linear-accelerator platforms are examples.

Fractionation and the four Rs

Fractionation divides a course into separate doses. The review uses conventional 1.8–2 Gy per fraction; hypofractionation uses larger fractions, while hyperfractionation uses smaller fractions, commonly more than once daily.

  • Repair: sublethal injury can be repaired between fractions.
  • Repopulation: surviving cells proliferate between treatments; this can help normal tissue but also allow tumour regrowth.
  • Redistribution: cells move through the cycle; G2/M phases are relatively radiosensitive.
  • Reoxygenation: formerly hypoxic tumour cells may become better oxygenated and more sensitive to later fractions.

These processes occur in both normal and malignant tissue to differing degrees. 'Normal cells always repair, tumour cells never repair' is too simple. Rapidly proliferating tumours often respond quickly, but growth rate alone does not determine radiosensitivity.

Curative, adjuvant and palliative intent

Definitive radiation is a main treatment intended to control a localized tumour. Adjuvant radiation treats microscopic residual risk after another therapy. Examples across oncology include selected breast, prostate, lung, head/neck, gynecologic, brain, skin, bladder, GI and soft-tissue cancers as well as lymphoma.

Palliative radiation reduces symptoms such as myeloma bone pain, bleeding, obstruction or neurologic compromise. Cord compression, SVC obstruction and airway compromise need urgent assessment; the appropriate sequence of steroids, systemic therapy, radiation or surgery depends on the disease and stability.

Acute toxicity follows the field

SiteExamples
Any fieldFatigue; local skin erythema or hair loss if relevant tissue is exposed.
Head/neckMucositis, taste change, xerostomia.
Brain/scalpScalp reaction and hair loss.
ChestEsophagitis/dysphagia, cough; breast swelling/erythema for breast fields.
Abdomen/pelvisNausea, vomiting, diarrhea, cramping; urinary or vaginal irritation depending on field.
Prostate/pelvic therapyUrinary/bowel effects; erectile dysfunction may emerge later.

Many acute effects accumulate and peak near the end of a course or shortly afterward; they are not necessarily worst immediately after the first fraction.

Subacute and late effects

Weeks to months: marrow suppression with large marrow fields; radiation pneumonitis, classically around 6–12 weeks after chest treatment; pericarditis; persistent dry mouth/fatigue; and transient Lhermitte phenomenon—electric/tingling sensations down the spine or limbs with neck flexion. Pneumonitis can cause cough, fever and dyspnea and may require corticosteroids after evaluation of alternatives.

Months to years: hypothyroidism after thyroid exposure, infertility with gonadal exposure, fibrosis/organ effects and secondary malignancy. The notes also list shingles in irradiated dermatomes. Fertility risk is dose-, age- and tissue-dependent; the slide's ovarian >2-Gy statement is not a universal sterility threshold. Modern fields and dose planning reduce some risks but do not eliminate them. Documented hypothyroidism is managed with thyroid hormone replacement.

QI and critical-appraisal material bundled with this lecture is covered in quality improvement and critical appraisal.

Review questions
Name the four Rs of radiobiology.

Repair, repopulation, redistribution and reoxygenation.

Cough and dyspnea several weeks after mediastinal radiation suggest which subacute toxicity?

Radiation pneumonitis, while also evaluating infection and other causes.

Quick reference

A second pass through the big patterns. Follow a link for the mechanism, diagnostic caveats, and treatment details.

One stem cell, two main families

The first two questions in anemia

1. What is the MCV? Microcytic (<80 fL), normocytic (80–100 fL), or macrocytic (>100 fL).
2. Is the reticulocyte response appropriate? Increased response suggests blood loss or destruction. An inadequate response suggests impaired production. Interpret against the degree and timing of anemia.
PatternOrganize the differentialRead more
MicrocyticIron deficiency, inflammation, thalassemia, lead and sideroblastic causes.Iron and microcytosis
Normocytic + low responseRenal disease, inflammation, early deficiency, marrow failure or infiltration.Marrow and production
Reticulocytosis + hemolysisUse smear, bilirubin, LDH, haptoglobin and DAT to identify the mechanism.Hemolysis
MacrocyticB12/folate deficiency and impaired DNA synthesis; alcohol/liver disease, hypothyroidism, reticulocytosis and marrow disease.Macrocytosis

MCV can be normal when opposing abnormalities coexist. A normal reticulocyte percentage can still be inadequate for an anemic patient.

Blood-film pattern library

Learn the appearance, then ask which mechanisms could produce it. A shape is a clue, not a diagnosis by itself.

Normal RBCBiconcave disc; central pallor.
Target cellThalassemia, HbC, liver disease.
SpherocyteHereditary spherocytosis or warm AIHA.
SchistocyteFragmentation: TMA, DIC, mechanical injury.
Sickle cellDeoxygenated HbS polymerization.
Teardrop cellMarrow fibrosis or infiltration.
Bite cellSplenic removal of oxidized Hb inclusions.
RouleauxStacking associated with increased plasma proteins.

Schematic illustrations. See the full smear discussion and original morphology chart (PDF p. 94).

Screening coagulation tests

ResultThink ofKey limit
PT prolonged; aPTT normalFactor VII, early vitamin K deficiency or warfarin effect.Pattern depends on severity and assay.
aPTT prolonged; PT normalIntrinsic factor deficiency, heparin, an inhibitor such as lupus anticoagulant.A prolonged aPTT does not always mean bleeding risk.
Both prolongedCommon pathway defects, severe liver disease, severe vitamin K deficiency, DIC or anticoagulant effects.Interpret alongside platelet count, fibrinogen, medications and history.
Both normal despite bleedingPlatelet/vWF disorders, factor XIII deficiency, vessel disorders or fibrinolytic abnormalities.Normal screening tests do not rule out a bleeding disorder.

Read the bleeding assessment · Read the mixing-test approach

Emergencies to recognize

Trigger in a vignetteImportant connectionFull explanation
Fever + severe neutropeniaRapid assessment and empiric antibiotics; infection signs may be muted.Febrile neutropenia
Promyelocytes + bleeding / DICSuspected APL is an emergency; treatment starts before genetic confirmation.APL and acute leukemia
Thrombocytopenia + MAHAConsider TTP/HUS and other TMAs; do not wait for the classic TTP pentad.TTP and HUS
Platelet fall after heparin + thrombosisSuspect immune HIT; stop heparin and assess non-heparin anticoagulation.HIT
Cell breakdown + potassium/phosphate/uric acid riseTumour lysis can cause arrhythmia and acute kidney injury.Tumour lysis syndrome
Very high blasts + respiratory/neurologic symptomsLeukostasis is a clinical emergency, not just a laboratory number.Leukostasis
Mediastinal mass + airway / venous obstructionAssess airway, superior vena cava obstruction and procedural risk.Mediastinal masses

These links summarize recognition patterns; each full section explains the clinical context and important exceptions.

Abbreviations, decoded

Keep this nearby when reading a blood count, drug table, or clinical vignette.

ADAMTS13
Enzyme that cleaves large von Willebrand factor multimers.
AIHA
Autoimmune hemolytic anemia.
ALL
Acute lymphoblastic leukemia.
AML
Acute myeloid leukemia.
ANC
Absolute neutrophil count.
APL
Acute promyelocytic leukemia.
aPTT
Activated partial thromboplastin time.
ATRA
All-trans retinoic acid.
BCR::ABL1
Fusion tyrosine kinase associated with CML and some ALL.
CBC
Complete blood count.
CLL
Chronic lymphocytic leukemia.
CML
Chronic myeloid leukemia.
CRAB
Hypercalcemia, renal impairment, anemia, bone lesions.
DAT
Direct antiglobulin test (direct Coombs test).
DIC
Disseminated intravascular coagulation.
DLBCL
Diffuse large B-cell lymphoma.
DOAC
Direct oral anticoagulant.
DVT
Deep vein thrombosis.
EPO
Erythropoietin.
ESA
Erythropoiesis-stimulating agent.
FISH
Fluorescence in situ hybridization.
G6PD
Glucose-6-phosphate dehydrogenase.
Hb
Hemoglobin.
Hct
Hematocrit: proportion of blood volume occupied by RBCs.
HIT
Heparin-induced thrombocytopenia.
HUS
Hemolytic uremic syndrome.
INR
International normalized ratio, derived from PT.
ITP
Immune thrombocytopenia.
LDH
Lactate dehydrogenase.
LMWH
Low-molecular-weight heparin.
MAHA
Microangiopathic hemolytic anemia.
MCV
Mean corpuscular volume: average RBC size.
MDS
Myelodysplastic neoplasm/syndrome.
MGUS
Monoclonal gammopathy of undetermined significance.
MPN
Myeloproliferative neoplasm.
PE
Pulmonary embolism.
PT
Prothrombin time.
PV
Polycythemia vera.
RDW
Red-cell distribution width: variation in RBC size.
SPEP
Serum protein electrophoresis.
TIBC
Total iron-binding capacity.
TKI
Tyrosine kinase inhibitor.
TLS
Tumour lysis syndrome.
TMA
Thrombotic microangiopathy.
TPO
Thrombopoietin.
TTP
Thrombotic thrombocytopenic purpura.
UFH
Unfractionated heparin.
VTE
Venous thromboembolism.
vWD
Von Willebrand disease.
vWF
Von Willebrand factor.

Sources & coverage

This guide brings together the supplied review deck and the available Week 9–12 MedFriend material. Explanations are reorganized and rewritten for short, connected reading. Repeated review slides and question-answer pairs are consolidated; logistical slides are not treated as exam content.

1
Schulich Reviews Heme Slides 2025

The supplied 228-page PDF. Week 9: pp. 1–94. Week 10: pp. 95–154. Weeks 11–12: pp. 155–228. Page numbers in this guide use the PDF viewer's numbering.

2
MedFriend · Foundations of Medicine · Block 3

The user-specified student-run website, including its note tables, figures, and decision trees. Roster: 33 entries across Weeks 9–12; 32 are represented by standalone or combined notes. Reviewed November 16, 2026.

The source gap: “Innate Immunity and WBCs” (Week 11, lecture 01) has no standalone note on the linked site. Related white-cell and innate-immunity fundamentals are included from the available materials; the absent lecture cannot be reconstructed with certainty. The original review deck also describes itself as non-exhaustive. Use the coverage map below to compare this guide with your own lecture objectives.

Lecture-by-lecture coverage map

A combined note counts toward each lecture it covers. Quality improvement and critical appraisal appear with Week 10 in the PDF and under Week 12 radiation oncology on the website; they are grouped once in the guide and linked from both.

LectureSource entryWhere to study it
9.01HematopoiesisSource note reviewedBlood cells, marrow and hemoglobinRead the CBC and blood film
9.02CBC and AnemiasSource note reviewedRead the CBC and blood film
9.03Approach to Microcytic AnemiaSource note reviewedIron biology and microcytic anemiaThalassemia and hemoglobin analysis
9.04Approach to Normocytic AnemiaSource note reviewedNormocytic anemia, marrow failure and MDSSickle cell disease and its emergencies
9.05Approach to Macrocytic AnemiaSource note reviewedMacrocytosis, vitamin B12 and folate
9.06Approach to Hemolytic AnemiaSource note reviewedRead the CBC and blood filmHemolysis and the direct antiglobulin testMembrane, enzyme and acquired nonimmune hemolysisAnemia treatment: replace, support, and find the cause
9.07HemoglobinopathiesCovered within combined source notesThalassemia and hemoglobin analysisSickle cell disease and its emergencies
9.08Myelodysplastic SyndromeSource note reviewedIron biology and microcytic anemiaNormocytic anemia, marrow failure and MDSMacrocytosis, vitamin B12 and folateAnemia treatment: replace, support, and find the cause
9.10Pharmacological Treatment of AnemiasCovered within combined source notesIron biology and microcytic anemiaAnemia treatment: replace, support, and find the cause
10.01Approach to a Bleeding PatientSource note reviewedHemostasis: building and removing a clotApproach to a bleeding patientHemophilia, von Willebrand disease and platelet dysfunctionBleeding in children and newbornsTransfusion: replace the missing component
10.02HemostasisSource note reviewedHemostasis: building and removing a clotCoagulation tests and adult coagulopathyVenous thromboembolism and thrombophilia
10.03Approach to Coagulopathy in AdultsSource note reviewedApproach to a bleeding patientCoagulation tests and adult coagulopathyHemophilia, von Willebrand disease and platelet dysfunction
10.04Coagulopathy in ChildrenSource note reviewedHemophilia, von Willebrand disease and platelet dysfunctionBleeding in children and newborns
10.05Approach to ThrombocytopeniaSource note reviewedThrombocytopenia and immune thrombocytopeniaTTP, HUS, HIT and DIC: low platelets can mean clottingVenous thromboembolism and thrombophiliaAnticoagulants: mechanisms, monitoring and reversal
10.06ThrombosisCovered within combined source notesVenous thromboembolism and thrombophilia
10.07Pharmacology and Reversal of AnticoagulantsSource note reviewedAnticoagulants: mechanisms, monitoring and reversal
11.01Innate Immunity and WBCsSource note missing · related fundamentals includedWhite cells and innate immunity
11.02Approach to LeukocytosisSource note reviewedWhite cells and innate immunityApproach to leukocytosisChronic leukemias: CML and CLLErythrocytosis and polycythemia veraThrombocytosis, myelofibrosis and pancytopenia
11.03Approach to LeukopeniaSource note reviewedLeukopenia and febrile neutropenia
11.04Approach to LeukemiaSource note reviewedSpecialized hematology testingAcute leukemia: AML, ALL and childrenAPL and leukemia emergenciesChronic leukemias: CML and CLL
11.05Approach to ErythrocytosisSource note reviewedErythrocytosis and polycythemia vera
11.06Approach to ThrombocytosisSource note reviewedThrombocytosis, myelofibrosis and pancytopenia
11.07Specialized Testing for Hematological MalignanciesSource note reviewedSpecialized hematology testing
11.08Leukemia in PediatricsSource note reviewedAcute leukemia: AML, ALL and children
11.10In-ClassCovered within combined source notesAcute leukemia: AML, ALL and childrenAPL and leukemia emergencies
12.01Adaptive ImmunityCovered within combined source notesAdaptive immunity and lymph-node anatomy
12.02Approach to LymphadenopathySource note reviewedAdaptive immunity and lymph-node anatomyApproach to lymphadenopathy
12.03Anatomy of a Mediastinal MassCovered within combined source notesAnatomy and approach to a mediastinal mass
12.04Classification and Testing for LymphomasSource note reviewedLymphoma: diagnosis, staging and prognosisHodgkin lymphomaNon-Hodgkin lymphoma and signature genetics
12.05Approach to LymphomaSource note reviewedLymphoma: diagnosis, staging and prognosisHodgkin lymphomaNon-Hodgkin lymphoma and signature genetics
12.06Multiple MyelomaSource note reviewedMonoclonal proteins and multiple myelomaAnatomy and approach to a mediastinal mass
12.07Pharmacology of Hematological MalignanciesSource note reviewedPharmacology of hematologic malignancies
12.08Radiation OncologySource note reviewedQuality improvement: change a process and measure itCritical appraisal and trial interpretationRadiation oncology

How disagreements are handled

Several source statements are inconsistent, simplified, or outdated. Relevant sections identify the correction and link supporting references. Particular attention is given to hemoglobin tetramers, vitamin units, anticoagulant mechanisms, emergency management, modern leukemia/myeloma criteria, and cancer-drug identities. Exact regimens and thresholds can depend on the clinical setting; course wording is identified where it differs.

Supporting references

These sources support targeted clarifications. The links also appear beside the relevant explanation.

  1. GeneReviews: alpha-thalassemia
  2. NHS PRCA guidance
  3. BSH MDS guidance
  4. ASH review of AIHA management
  5. International AIHA consensus
  6. sutimlimab trial
  7. BSH laboratory guideline
  8. WHO educational modules
  9. International diagnostic consensus
  10. CDC: sickle cell disease
  11. Canadian Paediatric Society acute-care guidance
  12. NIH folate reference
  13. NIH B12 reference
  14. BC iron-deficiency guideline
  15. BC B12/folate treatment guideline
  16. ASH/ISTH/NHF/WFH vWD management guideline
  17. CDC: vitamin K deficiency bleeding
  18. Canadian Blood Services: platelet transfusion
  19. ISTH diagnosis guideline
  20. 2025 ISTH update
  21. CDC: E. coli and HUS care
  22. Thrombosis Canada: HIT
  23. Canadian Blood Services: components
  24. Ontario transfusion recommendations
  25. Canadian Blood Services: transfusion reactions
  26. Thrombosis Canada: DVT diagnosis
  27. BC VTE guideline
  28. Thrombosis Canada: duration
  29. Thrombosis Canada: DOAC bleeding
  30. UFH, LMWH and fondaparinux guide
  31. COSTaRS fever-with-neutropenia guide
  32. eviQ immediate management
  33. WHO classification update
  34. NCI pediatric AML evidence
  35. NCI blinatumomab
  36. NCI inotuzumab
  37. European LeukemiaNet APL recommendations
  38. eviQ TLS guidance
  39. MD Anderson TLS algorithm
  40. NICE lymphoma biopsy guidance
  41. ACR advanced Hodgkin review
  42. NCI Hodgkin treatment evidence
  43. ASCO living myeloma guideline
  44. IMWG diagnostic criteria
  45. BSH/UK Myeloma Forum criteria
  46. IMWG PCL consensus
  47. Original IMWG R-ISS report
  48. ESMO thymic-tumour guidance
  49. NCI brentuximab mechanism
  50. FDA safety action
↑ Top